CN112585270A - Compositions and methods for assessing or improving brain function, learning ability or memory - Google Patents
Compositions and methods for assessing or improving brain function, learning ability or memory Download PDFInfo
- Publication number
- CN112585270A CN112585270A CN201880096673.8A CN201880096673A CN112585270A CN 112585270 A CN112585270 A CN 112585270A CN 201880096673 A CN201880096673 A CN 201880096673A CN 112585270 A CN112585270 A CN 112585270A
- Authority
- CN
- China
- Prior art keywords
- subject
- mettl3
- composition
- memory
- body part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 109
- 230000003925 brain function Effects 0.000 title claims abstract description 41
- 230000013016 learning Effects 0.000 title claims description 78
- 230000015654 memory Effects 0.000 title claims description 45
- 101000967135 Homo sapiens N6-adenosine-methyltransferase catalytic subunit Proteins 0.000 claims abstract description 183
- 102100040619 N6-adenosine-methyltransferase catalytic subunit Human genes 0.000 claims abstract description 183
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 90
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 82
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 108060004795 Methyltransferase Proteins 0.000 claims abstract description 37
- 102000016397 Methyltransferase Human genes 0.000 claims abstract description 37
- 230000028252 learning or memory Effects 0.000 claims abstract description 27
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 23
- 230000002708 enhancing effect Effects 0.000 claims abstract description 23
- 230000001965 increasing effect Effects 0.000 claims abstract description 23
- 229960005305 adenosine Drugs 0.000 claims abstract description 22
- TYEYVCQGIWVYQJ-SPIULWCRSA-N (2r,3r,4s,5r)-2-(6-amino-6-methyl-8h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N=C2C(C)(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TYEYVCQGIWVYQJ-SPIULWCRSA-N 0.000 claims abstract description 14
- 210000001320 hippocampus Anatomy 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 46
- 210000004556 brain Anatomy 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 41
- 230000007787 long-term memory Effects 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 208000026139 Memory disease Diseases 0.000 claims description 35
- 241000700605 Viruses Species 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 21
- 206010027175 memory impairment Diseases 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 15
- 238000007596 consolidation process Methods 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 12
- 230000004936 stimulating effect Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 208000000044 Amnesia Diseases 0.000 claims description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 208000006888 Agnosia Diseases 0.000 claims description 7
- 241001047040 Agnosia Species 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000031091 Amnestic disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 230000006986 amnesia Effects 0.000 claims description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 5
- 230000003340 mental effect Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 117
- 238000012360 testing method Methods 0.000 description 73
- 101150084627 Mettl3 gene Proteins 0.000 description 51
- 238000012549 training Methods 0.000 description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 239000012472 biological sample Substances 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000006735 deficit Effects 0.000 description 16
- 108091070501 miRNA Proteins 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 16
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000027928 long-term synaptic potentiation Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 201000003723 learning disability Diseases 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000035939 shock Effects 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 108700002232 Immediate-Early Genes Proteins 0.000 description 10
- 208000020358 Learning disease Diseases 0.000 description 10
- 238000000692 Student's t-test Methods 0.000 description 10
- 230000003750 conditioning effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 9
- 230000005056 memory consolidation Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000006403 short-term memory Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000012347 Morris Water Maze Methods 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108020004491 Antisense DNA Proteins 0.000 description 7
- 239000003816 antisense DNA Substances 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 230000005978 brain dysfunction Effects 0.000 description 7
- 230000001143 conditioned effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 6
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 6
- 102000051619 SUMO-1 Human genes 0.000 description 6
- 210000004727 amygdala Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000001638 cerebellum Anatomy 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000000478 neocortex Anatomy 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 210000002442 prefrontal cortex Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 5
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 5
- 108700038981 SUMO-1 Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000007087 memory ability Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002243 primary neuron Anatomy 0.000 description 5
- 210000001176 projection neuron Anatomy 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000946 synaptic effect Effects 0.000 description 5
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 4
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 241000555745 Sciuridae Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010201 enrichment analysis Methods 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- 101001006370 Actinobacillus suis Hemolysin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000187129 Bacopa monnieria Species 0.000 description 2
- 235000015418 Bacopa monnieria Nutrition 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101001013582 Homo sapiens N6-adenosine-methyltransferase non-catalytic subunit Proteins 0.000 description 2
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 2
- 101000666873 Homo sapiens Protein virilizer homolog Proteins 0.000 description 2
- 101000959153 Homo sapiens RNA demethylase ALKBH5 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100031578 N6-adenosine-methyltransferase non-catalytic subunit Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 102100038288 Protein virilizer homolog Human genes 0.000 description 2
- 102100039083 RNA demethylase ALKBH5 Human genes 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- 102100024542 Small ubiquitin-related modifier 2 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229960001284 citicoline Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000005257 cortical tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 210000005110 dorsal hippocampus Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 238000013095 identification testing Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007786 learning performance Effects 0.000 description 2
- 108091007427 let-7g Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QUTYKIXIUDQOLK-PRJMDXOYSA-N 5-O-(1-carboxyvinyl)-3-phosphoshikimic acid Chemical compound O[C@H]1[C@H](OC(=C)C(O)=O)CC(C(O)=O)=C[C@H]1OP(O)(O)=O QUTYKIXIUDQOLK-PRJMDXOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 101150068685 BTG2 gene Proteins 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 241001663879 Deltaretrovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150114117 EGR1 gene Proteins 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001089723 Metaphycus omega Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- 101150088803 NR4A1 gene Proteins 0.000 description 1
- 101150082200 Npas4 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012220 PCR site-directed mutagenesis Methods 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 241000785681 Sander vitreus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000713656 Simian foamy virus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710081623 Small ubiquitin-related modifier 1 Proteins 0.000 description 1
- 101710081711 Small ubiquitin-related modifier 2 Proteins 0.000 description 1
- 101710081626 Small ubiquitin-related modifier 3 Proteins 0.000 description 1
- 102100024535 Small ubiquitin-related modifier 4 Human genes 0.000 description 1
- 101710081624 Small ubiquitin-related modifier 4 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 108010031180 cypridina luciferase Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 108700025184 hepatitis B virus X Proteins 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091064218 miR-1224 stem-loop Proteins 0.000 description 1
- 108091068881 miR-1226 stem-loop Proteins 0.000 description 1
- 108091044253 miR-1981 stem-loop Proteins 0.000 description 1
- 108091023968 miR-330 stem-loop Proteins 0.000 description 1
- 108091037240 miR-423 stem-loop Proteins 0.000 description 1
- 108091025542 miR-668 stem-loop Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000021127 protein binding proteins Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012031 short term test Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000004477 skin sarcoma Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions and methods for improving brain function or enhancing learning or memory are provided. The composition may comprise increasing METTL3 (N) in at least one body part of a subject6-adenosine methyltransferase 70kDa subunit). The methods can include administering to a subject a composition comprising one or more agents that increase the efficacy of METTL3 in at least one body part of the subject. Methods for assessing learning or memory ability of a subject are also provided. The method may comprise assessing N in at least one body part of the subject6-methyladenosine (m)6A) The level of the protein of interest is,and m is6A or said m6The level of the a-related protein is compared to a standard level. The method may further comprise basing the m6A or said m6Comparing the level of the a-related protein to a standard level to determine the learning or memory ability of the subject.
Description
Technical Field
The present application relates generally to assessment or improvement of physiological and/or psychological functions, and more particularly to compositions and methods for improving brain function, learning ability or memory, and methods for assessing brain function, learning ability or memory.
Background
Memory and learning play an important role in people's daily life. Many people suffer from memory and learning disorders or deficits such as agnosia, alzheimer's disease, amnesia and dementia. These people often have difficulty remembering information and learning new skills, and thus suffer from pain and a reduction in quality of life. Furthermore, persons with normal memory and learning ability often desire to enhance such ability, or to prevent the memory and learning ability from gradually declining with age. Memory and learning ability depend to a large extent on the function of the brain to receive, store, consolidate and retrieve information. Brain function may be associated with neuronal plasticity and expression of certain genes (e.g., early response genes). Accordingly, it is desirable to develop compositions and methods for assessing and/or improving brain function, learning ability, or memory in healthy subjects, as well as subjects suffering from disorders or deficiencies.
Disclosure of Invention
According to an aspect of the present application, a method is provided. The methods may include administering to a subject a composition for improving brain function or enhancing learning or memory in the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
In some embodiments, the subject may be a human or an animal.
In some embodiments, the subject may have a learning or memory disorder.
In some embodiments, the subject may have a learning or memory deficit.
In some embodiments, the subject may have agnosia, alzheimer's disease, amnesia, brain trauma, or dementia.
In some embodiments, the subject may be mentally healthy.
In some embodiments, the at least one body part of the subject may comprise the brain of the subject.
In some embodiments, the at least one body part of the subject may comprise the hippocampus of the subject.
In some embodiments, the one or more agents may be configured to increase the amount of METTL3 in the at least one body part.
In some embodiments, the one or more agents may include a METTL3 peptide.
In some embodiments, the one or more reagents can include a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the one or more reagents can include an engineered vector comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the one or more reagents can include an engineered virus comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the virus may comprise an adeno-associated virus, an adenovirus, a lentivirus, or a sendai virus.
In some embodiments, the one or more agents may be configured to increase METTL3 expression by stimulating a positive factor that enhances METTL3 expression.
In some embodiments, the one or more agents may be configured to increase METTL3 expression by inhibiting a negative factor that decreases METTL3 expression.
In some embodiments, the one or more reagents may comprise an antibody.
In some embodiments, the one or more agents may be configured to stimulate METTL3 activity in the at least one body part.
In some embodiments, the one or more agents may include a METTL3 agonist.
In some embodiments, the one or more agents may be configured to increase METTL3 activity by stimulating a positive factor that enhances METTL3 activity.
In some embodiments, the one or more agents may be configured to increase METTL3 activity by inhibiting a negative factor that decreases METTL3 activity.
In some embodiments, administering the composition to the subject may comprise administering the composition to the skin of the subject.
In some embodiments, administering a composition to a subject may comprise injecting the composition into the subject.
In some embodiments, administering a composition to a subject may comprise orally administering the composition to the subject.
In some embodiments, the composition may be configured as a suppository.
According to another aspect of the present application, a method is provided. The methods can include administering to a subject a composition to enhance learning ability of the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit) One or more agents of potency.
According to another aspect of the present application, a method is provided. The methods may include administering to a subject a composition to enhance memory in the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The methods can include administering to a subject a composition for enhancing long term memory consolidation in the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The methods can include administering to a subject a composition for enhancing long term memory consolidation in the subject, the composition comprising increasing METTL3 (N) in the subject's hippocampus6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The methods can include administering to a subject a composition for improving brain function in the subject with a mental disorder, the composition comprising increasing METTL3 (N) in the hippocampus of the subject6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The methods can include administering to a subject a composition for enhancing long-term memory consolidation in the subject having a memory deficit, the composition including increasing METTL3 (N) in the hippocampus of the subject6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The method can include administering to a subject a composition for enhancing long-term memory consolidation in the subject who does not suffer from a memory deficit, the composition including in the subject's seaIncreasing METTL3 (N) in horses6-adenosine methyltransferase 70kDa subunit).
According to another aspect of the present application, a method is provided. The method may comprise administering to a subject a composition for improving brain function or enhancing learning or memory in the subject, the composition comprising increasing N in at least one body part of the subject6-methyladenosine (m)6A) An abundance of one or more reagents.
According to another aspect of the present application, a method for assessing learning or memory of a subject is provided. The method may comprise assessing N in at least one body part of the subject6-methyladenosine (m)6A) The level of the protein of interest, and6a or said m6The level of the a-related protein is compared to a standard level. The method may further comprise basing the m6A or said m6Comparing the level of the a-related protein to a standard level to determine learning or memory of the subject.
In some embodiments, the m6The a-related protein may be METTL3 protein.
In some embodiments, the at least one body part of the subject may comprise the hippocampus of the subject.
In some embodiments, the standard level is determined by evaluating the m of at least one body part of a control subject6Levels of a-related protein.
According to yet another aspect of the present application, a composition is provided. The composition may be configured to improve brain function or enhance learning or memory of the subject. The composition may comprise increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
In some embodiments, the subject may be a human or an animal.
In some embodiments, the subject may have a learning or memory disorder.
In some embodiments, the subject may have a learning or memory deficit.
In some embodiments, the subject may have agnosia, alzheimer's disease, amnesia, brain trauma, or dementia.
In some embodiments, the subject may be mentally healthy.
In some embodiments, the at least one body part of the subject may comprise the brain of the subject.
In some embodiments, the at least one body part of the subject may comprise the hippocampus of the subject.
In some embodiments, the one or more agents may be configured to increase the amount of METTL3 in the at least one body part.
In some embodiments, the one or more agents may include a METTL3 peptide.
In some embodiments, the one or more reagents can include a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the one or more reagents can include an engineered vector comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the one or more reagents can include an engineered virus comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
In some embodiments, the virus may comprise an adeno-associated virus, an adenovirus, a lentivirus, or a sendai virus.
In some embodiments, the one or more agents may be configured to increase METTL3 expression by stimulating a positive factor that enhances METTL3 expression.
In some embodiments, the one or more agents may be configured to increase METTL3 expression by inhibiting a negative factor that decreases METTL3 expression.
In some embodiments, the one or more reagents may comprise an antibody.
In some embodiments, the one or more agents may be configured to stimulate METTL3 activity in the at least one body part.
In some embodiments, the one or more agents may include a METTL3 agonist.
In some embodiments, the one or more agents may be configured to increase METTL3 activity by stimulating a positive factor that enhances METTL3 activity.
In some embodiments, the one or more agents may be configured to increase METTL3 activity by inhibiting a negative factor that decreases METTL3 activity.
Additional features of the present application will be set forth in part in the description which follows. Additional features of some aspects of the present application will be apparent to those of ordinary skill in the art in view of the following description and accompanying drawings, or in view of the production or operation of the embodiments. The features of the present application may be realized and obtained by means of the instruments and methods and by means of the methods and combinations set forth in the detailed examples discussed below.
Drawings
The present application will be further described by way of exemplary embodiments. These exemplary embodiments will be described in detail by means of the accompanying drawings. It should be noted that the drawings are not to scale. These embodiments are non-limiting exemplary embodiments in which like reference numerals represent similar structures throughout the several views of the drawings, and wherein:
FIGS. 1A-1F show exemplary results of a postnatal knockout of Mettl3 in the hippocampus resulting in a prolonged Long Term Memory (LTM) consolidation process, according to some embodiments of the present application;
2A-2D show exemplary results of electrophysiological testing of a hippocampus knockout Mettl3 according to some embodiments of the present application;
FIGS. 3A-3D illustrate METTL3 passing through its m according to some embodiments of the present application6Exemplary results of modulation of long-term memory formation by A methyltransferase function;
FIGS. 4A-4D illustrate dynamically adjusting m during memory consolidation according to some embodiments of the present application6Exemplary results of A methylation;
FIGS. 5A-5F illustrate m according to some embodiments of the present application6Exemplary results of a promoting translation of early response genes following activity induction;
6A-6E illustrate exemplary results of overexpression of METTL3 enhancing the development of long term memory according to some embodiments of the present application;
FIG. 7 illustrates an exemplary proposed model according to some embodiments of the present application;
figures 8A-8H show exemplary results of brain gross morphology characterization of Mettl3 cKO mice according to some embodiments of the present application;
figures 9A-9F show exemplary results of Mettl3 cKO mice showing no differences in locomotion, exploration, and anxiety compared to the control group according to some embodiments of the present application;
10A-10C show exemplary results of the electrophysiological properties of cKO mice, according to some embodiments of the present application;
11A-11B illustrate exemplary results of an analysis of transcriptome changes during early time points after training according to some embodiments of the present application;
FIG. 12 shows exemplary results of MeRIP-qPCR validation according to some embodiments of the present application; and
fig. 13A-13B show exemplary results of overexpression of Mettl3 in hippocampus or primary neurons according to some embodiments of the present application.
Detailed Description
The following description is presented to enable any person skilled in the art to make and use the application, and is provided in the context of a particular application and its requirements. It will be apparent to those skilled in the art that various modifications to the disclosed embodiments are possible, and that the general principles defined in this application may be applied to other embodiments and applications without departing from the spirit and scope of the application. Thus, the present application is not limited to the described embodiments, but should be accorded the widest scope consistent with the claims.
The terminology used herein is for the purpose of describing particular example embodiments only and is not intended to be limiting. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises," "comprising," "includes" and/or "including," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
The combination of these features of the present application, as well as the methods of operation and functions of the structure of the related elements, and the parts and economies of manufacture, will become more apparent upon consideration of the following description with reference to the accompanying drawings, all of which form a part of this specification. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the application. It should be understood that the drawings are not to scale.
Compositions and methods for improving brain function or enhancing learning or memory, and methods for assessing brain function, learning or memory are provided. In some embodiments, the composition can comprise one or more agents that increase METTL3 (N) in at least one body part of the subject (e.g., the brain of the subject)6Adenosine methyltransferase 70kDa subunit). In some embodiments, the one or more agents may be configured to increase the amount of METTL3 or METTL3 activity in at least one body part of the subject. In some embodiments, the subject may be mentally healthy, or the subject may have a learning disorder, a memory disorder, a learning deficit, a memory deficit, or the like, or any combination thereof. In some embodiments, a method for improving brain function or enhancing learning or memory may comprise administering to a subject a composition as described above. In some embodiments, the present disclosure also includes compositions disclosed hereinUse for the manufacture of a medicament or food supplement for the treatment of a disorder or defect in brain function, learning ability or memory in a subject. In some embodiments, the present disclosure also includes use of a composition disclosed herein in the manufacture of a medicament or food supplement for improving a disorder or deficiency in brain function, learning ability, or memory in a subject. In some embodiments, the composition can be administered to the subject by oral administration, injection administration, topical administration, and the like. In some embodiments, the composition may be configured as a suppository. In some embodiments, a method for assessing brain function, learning ability, or memory of a subject may include assessing N of at least one body part of the subject6-methyladenosine (m)6A) Or m is6Levels of a-related proteins (e.g., METTL3, METTL 14). In some embodiments, m may be6A or m6The estimated level of the a-related protein is compared to a standard level. In some embodiments, may be based on m6A (or m)6A-related protein) to determine brain function, learning ability, or memory of the subject. In response to determining m6A (or m)6A-related protein) below the corresponding standard level, it can be determined that the subject has a relatively low brain function, learning ability, or memory.
As used herein, the term "potency" refers to the total catalytic ability of an enzyme (e.g., RNA, protein, peptide, or fragment thereof) in a subject or in certain regions of a subject (e.g., a body part, tissue, or organ). The region may include, but is not limited to, the entire body or a portion of the body of the subject. In some embodiments, the subject may be a human or non-human animal. In some embodiments, a portion of a body may include an organ, tissue, blood vessel, or portion thereof, or a combination thereof. By way of example only, the region may include the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof. In certain embodiments, the area includes a human hippocampus. In some embodiments, the effectiveness of an enzyme may depend on the total amount (or concentration) of the enzyme in the region and/or the activity of the enzyme in the region. The term "activity" of an enzyme refers to the catalytic ability of a certain number of enzymes in that region.
As used herein, the term "brain function" refers to the ability of the brain to receive, process, and/or store various information, and/or to control and/or modulate various biological activities. In some embodiments, brain function may be affected or impaired by one or more factors such as aging, brain trauma, tumors, physiological disorders, and the like, or any combination thereof. If the brain function is abnormal, one or more abilities related to the subject's brain function (e.g., understanding, memory, reading, spoken language, hearing, vision, learning, etc.) may be affected. In some embodiments, brain function may be improved by the compositions and methods described herein.
As used herein, the term "memory" refers to the ability to acquire information stored in the brain that can be retrieved, or encode, store, register, access and/or retrieve the acquired information. In some embodiments, the terms "memory" and "memorability" are used interchangeably herein to refer to the ability to encode, store, register, access and/or retrieve information. In some embodiments, the memory may include short-term memory and/or long-term memory. In some embodiments, short-term memory may refer to the ability to save a small amount of information in the brain over a short period of time (e.g., 1s, 2s, 3s, 4s, 5s, 10s, 15s, 20s, 25s, 30s, etc.). In some embodiments, the short-term memory can develop rapidly and can last for a relatively short period of time (e.g., one or more seconds, one or more minutes, one or more hours, one or more days, etc.). In some embodiments, long-term memory may be a stage in the Atkinson-Shiffrin memory model where knowledge of information may be maintained indefinitely. In some embodiments, the rate of development of long-term memory may be slower and may last for a relatively longer period of time (e.g., one or more days, one or more weeks, one or more months, one or more years, etc.) than the short-term memory. In some embodiments, the newly acquired information may be initially stored in the brain in a vulnerable state and may tend to be gradually forgotten by the subject. The fragile state of the acquired information may transition to a relatively stable state in the brain during memory integration, and thus, the acquired information is less likely to be forgotten by the subject. In some embodiments, the memory consolidation process may occur naturally over time, or as the same acquired information (or related information) is retrieved.
As used herein, the term "learning capabilities" refers to the ability to obtain new information, knowledge and/or skills through a process that includes experiencing, learning, or receiving training, etc. In some embodiments, learning capabilities may depend at least in part on the development of memory. For example, during learning, known information in existing memory may be retrieved and used to generate new information, such as new understandings, knowledge, skills, and the like, or any combination thereof. In some embodiments, the new information may be stored in the brain for further learning processes. Thus, in some embodiments, if a subject suffers from a memory disorder, it may be indicated that the subject also suffers from a learning disorder. In some embodiments, a memory impairment and/or a learning impairment may be induced or indicated if the brain function used to receive, process and/or store information is abnormal.
According to an aspect of the present application, there is provided a composition configured to improve brain function or enhance learning or memory of a subject. In some embodiments, the composition may comprise a peptide configured to increase m in at least one body part of the subject6A level of one or more agents. In some embodiments, the composition may include a METTL3 (N) configured to increase in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
In some embodiments, the subject may be a human or an animal. For example, the subject may be an infant, child, adolescent, young adult, middle aged or elderly human. In some embodiments, the subject may be a vertebrate or an invertebrate. Exemplary animals can be monkeys, orangutans, tigers, cats, dogs, rabbits, ferrets, pigs, gerbils, hamsters, yellow rats, mice, guinea pigs, hedgehogs, pouzoles, yellow squirrels, marmot, squirrels, fish, turtles, and the like, or any combination thereof. In some embodiments, the subject may be a mammal. In some embodiments, the subject may include a companion animal (also referred to as a "pet"), an animal of a protected species, an animal used for scientific research, an animal assisting police (e.g., a police dog), and the like, or any combination thereof. In some embodiments, animals used for scientific research can include normal animal models (e.g., animals that have not received any experimental treatment) and/or test animal models (e.g., animals that have received one or more experimental treatments). In some embodiments, the test animal model may have received one or more experimental treatments relating to toxicology testing, disease treatment testing, xenograft testing, drug testing, defense testing, behavioral testing (e.g., long term memory testing, short term memory testing, learning testing). In some embodiments, the one or more experimental treatments may include, but are not limited to, administering a test composition (e.g., a drug, a supplement or an active ingredient thereof, or a food, a beverage, etc.) to the test animal model, altering the conditions of growth and development of the test animal model, modifying one or more genes of the test animal model, etc., or any combination thereof.
In some embodiments, the subject may suffer from a learning deficit and/or a memory deficit. As used herein, the term "learning deficit" (also referred to as learning disability) may refer to a subject having an unusually difficult to learn information, knowledge and/or skills, or having symptoms of a disease associated with learning disability or reduced learning ability. As used herein, the term "memory deficit" may refer to a symptom of a subject having exceptional difficulty encoding, storing, registering, accessing, and/or obtaining learned information, or having a disease associated with memory disability or memory loss. In some embodiments, the subject may have a learning disorder and/or a memory disorder. As used herein, the term "learning disorder" may refer to a neurological development, neural structure, or neurochemical problem that causes a person with normal intellectual potential to encounter, in their learning function, an abnormal difficulty that cannot be explained with insufficient educational opportunities or emotional or mental disorders. As used herein, the term "memory disorder" may refer to damage to one or more neuro-anatomical structures or the result of a neurochemical problem that has impeded the storage, retention, and/or recovery of memory. In some embodiments, the subject may be impaired in brain function (i.e., brain dysfunction) in receiving, processing, and/or storing information, and this may lead to memory impairment and/or learning impairment. In some embodiments, the learning disorder, learning deficit, memory disorder, memory deficit, and/or brain dysfunction may be caused by one or more factors, such as developmental problems, aging, brain trauma, tumors, physiological disorders, and the like, or any combination thereof. For example, the subject may have traumatic brain injury, agnosia, alzheimer's disease, amnesia, dementia, huntington's disease, parkinson's disease, weirnike-koxsackov syndrome, or the like, or any combination thereof. As another example, a subject may have a tumor located in or near the central nervous system (e.g., the brain), which may affect the normal biological functions of the brain.
In some embodiments, the composition can be administered to a subject to treat or alleviate a learning disorder, learning deficit, memory disorder, memory deficit, and/or brain dysfunction. For example, the composition may be configured to reduce, alleviate or eliminate one or more symptoms of a learning disorder, learning deficit, memory disorder, memory deficit, and/or brain dysfunction, and/or reduce or slow further progression. In some embodiments, the compositions may be administered to a subject to improve the brain's ability to receive, process, and store various information, and/or the ability to control and/or modulate various biological activities; enhancing the ability of the subject to encode, store, register, access and/or retrieve the acquired information, and/or enhancing the ability of the subject to obtain new information, knowledge and/or skills.
In some embodiments, the subject may be mentally healthy. As used herein, the term "mental health" refers to the absence of learning disorders, learning deficits, memory disorders, memory deficits, and/or brain dysfunction as described above. A mentally healthy subject may have normal learning, memory and/or brain function. In some embodiments, the composition can be administered to a mental healthy subject to improve brain function, enhance learning and/or memory in the subject, or prevent a decline in learning and/or memory (e.g., with age). In some embodiments, the compositions may be administered to a subject at risk of learning disorders, learning deficits, memory disorders, memory deficits, and/or brain dysfunction to prevent these and other disorders. In some embodiments, the subject may be an elderly human. In some embodiments, the subject may be an infant, child, juvenile, or adult from a family with a genetic history associated with a learning deficit, memory deficit, and/or brain dysfunction.
In some embodiments, the composition may include a peptide configured to increase m6A methyltransferase activity of a. m is6The a methyltransferase may include, but is not limited to, METTL3, METTL14, WTAP, KIAA1429, or the like, or a fragment thereof, or any combination thereof. In some embodiments, the composition may comprise a peptide configured to reduce m6A Demethiylase potency to increase m6One or more agents of A abundance. m is6A demethylases may include, but are not limited to, FTO, ALKBH5, and the like, or fragments thereof, or any combination thereof. In the following description, the compositions and methods for increasing the efficacy of METTL3 are provided for illustrative purposes only and are not intended to limit the scope of the present application. It should be noted that similar strategies may also be applied to add one or more other m6Compositions and methods for reducing the potency of A methyltransferases, or reducing the potency of one or more m6A demethylase or other m6Compositions and methods for the efficacy of A-related enzymes or any combination thereof.
In some embodiments, the composition may include one or more agents that increase the efficacy of METTL3 in at least one body part of the subject. METTL3 is N6-adenosine methyltransferase 70kDa subunit. As used herein, the term "METTL 3 potency" may refer to METTL3 catalyzing in at least one body part of a subjectTotal capacity for methylation of RNA (e.g., mRNA) of (a). In some embodiments, METTL3 can catalyze methylation of mRNA to facilitate translation of mRNA. In some embodiments, METTL3 can recognize and/or facilitate translation of methylated mRNA. In some embodiments, METTL3 can bind chromatin. For example, METTL3 can bind DNA at the transcriptional initiation region (e.g., promoter). In some embodiments, METTL3 may be determined by dependence on m6A or independently of m6The mechanism of a promotes translation of genes (e.g., neuronal early response genes) to regulate memory formation and/or memory consolidation. In some embodiments, METTL3 (or other m)6A methyltransferase) may enhance long-term potentiation (LTP). As used herein, the term "long-term potentiation" refers to the persistent enhancement of synapses based on recent patterns of synaptic activity. In some embodiments, the recent pattern of synaptic activity may produce a persistent increase in signaling between two neurons. In some embodiments, enhancement of LTP may result in improvement in brain function, learning ability, and memory (e.g., long-term memory). In some embodiments, the agent that increases the efficacy of METTL3 may be configured to increase the amount of METTL3 in at least one body part of the subject and/or increase the activity of METTL3 in at least one body part unit number of the subject. In some embodiments, the at least one body part may comprise an organ, tissue or part thereof. By way of example only, the at least one body part may include, but is not limited to, the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof.
In some embodiments, the efficacy of METTL3 may be increased by increasing the amount of METTL3 peptide or increasing the activity of METTL3 peptide in at least one body site. As used herein, the term "METTL 3 peptide" refers to a full-length METTL3 protein, or a fragment of METTL3 protein that retains the efficacy of METTL3 (i.e., the ability of the METTL3 peptide to catalyze methylation of RNA (e.g., mRNA)).
In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may comprise a METTL3 peptide. In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site can include a METTL3cDNA sequence and/or a fragment of METTL3cDNA sequence. As used herein, Mettl3cDNA sequence and/or fragments thereof can refer to DNA sequences encoding Mettl3 peptides. In some embodiments, the agent that increases the efficacy of METTL3 in at least one body part may include a METTL3mRNA sequence and/or a fragment of a METTL3mRNA sequence. As used herein, a METTL3mRNA sequence and/or a fragment of METTL3mRNA sequence may refer to mRNA transcribed from a fragment of METTL3cDNA sequence and/or METTL3cDNA sequence. In some embodiments, a Mettl3cDNA sequence, a fragment of a Mettl3cDNA sequence, a Mettl3mRNA sequence, and/or a fragment of a Mettl3mRNA sequence can increase expression of a Mettl3 peptide in at least one body site, thereby increasing the amount of expression of a Mettl3 peptide in at least one body site.
In some embodiments, an agent that increases the efficacy of METTL3 in at least one body site may include an engineered METTL3 peptide, an engineered METTL3 peptide refers to a mutant form of full-length METTL3 or a METTL3 fragment that retains catalytic activity, and a peptide comprising a wild-type or mutant METTL3 peptide coupled or linked to a carrier agent. For example, the carrier agent may be a carrier nanoparticle or a carrier peptide configured to facilitate passage of the METTL3 peptide across the Blood Brain Barrier (BBB). In certain embodiments, liposomes can be loaded onto carrier nanoparticles, thereby facilitating the transfer of the engineered METTL3 peptide across the BBB. In certain embodiments, the vector peptide may be a peptide having a sequence obtained from the brainpps database and capable of passing through the BBB, e.g., by active transport.
In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site can include an engineered vector comprising a METTL3cDNA sequence or a fragment of METTL3cDNA sequence. In some embodiments, the agent that increases the efficacy of METTL3 in at least one body part may comprise an engineered vector comprising a METTL3mRNA sequence or a fragment of a METTL3mRNA sequence. Vectors may include, but are not limited to, plasmids, cosmids, synthetic nucleic acids, artificial chromosomes, and the like. By way of example only, a Mettl3cDNA sequence, a fragment of Mettl3cDNA sequence, a Mettl3mRNA sequence, and/or a fragment of Mettl3mRNA sequence can be incorporated into nucleic acids, respectively, to produce engineered nucleic acids. In some embodiments, the engineered nucleic acid can be used directly to transfect cells in at least one body part of a subject.
In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may comprise an engineered virus. The engineered virus can include a Mettl3cDNA sequence, a fragment of Mettl3cDNA sequence, a Mettl3mRNA sequence, and/or a fragment of Mettl3mRNA sequence. In some embodiments, the engineered nucleic acid can be introduced into a virus to obtain an engineered virus. For example, the virus may include adenovirus, adeno-associated virus, sendai virus (SeV), retrovirus, polyoma virus, epstein-barr virus, and the like, or any combination thereof. In some embodiments, the retrovirus may include one or more viruses from the alpha retrovirus genus (e.g., avian leukemia virus), the bertaro retrovirus genus (e.g., mouse mammary tumor virus), the gamma retrovirus genus (e.g., murine leukemia virus), the delta retrovirus genus (e.g., bovine leukemia virus), the epsilon retrovirus genus (e.g., Walleye skin sarcoma virus), the lentivirus genus (e.g., human immunodeficiency virus), the foamy virus genus (e.g., simian foamy virus), and the like, or any combination thereof. In some embodiments, the engineered virus may infect one or more cells in at least one body site, and expression of the METTL3 peptide may be increased in the at least one body site.
In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may comprise a positive factor that enhances METTL3 expression. In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may be configured to increase METTL3 expression by stimulating a positive factor that enhances METTL3 expression. For example, the agent may include a peptide, a lipid, a polysaccharide, a nucleic acid, a steroid, or any combination thereof.
In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may be configured to increase METTL3 expression by inhibiting a negative factor that decreases METTL3 expression. In some embodiments, the negative factor that reduces METTL3 expression may include microrna (mirna), antisense DNA, small interfering rna (sirna), or the like, or any combination thereof. In some embodiments, the complementary strand of the miRNA, antisense DNA, and/or siRNA can bind to the METTL3mRNA sequence or a fragment of the METTL3mRNA sequence through a base pairing mechanism, such that the METTL3mRNA sequence can be silenced, and expression of the METTL3 peptide can be inhibited. In some embodiments, an agent that inhibits a negative factor may include an inhibitor of miRNA, antisense DNA, and/or siRNA, an enzyme that degrades miRNA, antisense DNA, and/or siRNA, a nucleic acid encoding an enzyme that degrades miRNA, antisense DNA, and/or siRNA, a vector comprising a nucleic acid encoding an enzyme that degrades miRNA, antisense DNA, and/or siRNA, an engineered virus including an enzyme that encodes an enzyme that degrades miRNA, antisense DNA, and/or siRNA, and the like, or any combination thereof. By way of example only, mirnas that reduce METTL3 expression may include let-7g mirnas that target the 3 '-UTR (3' untranslated region) of METTL3 mRNA. Exemplary agents that inhibit let-7g mirnas and increase METTL3 expression may include, but are not limited to, mammalian hepatitis b virus X protein binding protein (HBXIP) or fragments thereof. In some embodiments, the agent that increases the efficacy of METTL3 in at least one body site may comprise an antibody. In some embodiments, the antibody can specifically bind to a negative factor that reduces METTL3 expression. For example, an antibody can include an IgG, IgM, IgA, IgD, or IgE molecule or an antigen-specific fragment thereof (e.g., Fab fragment, Fv fragment, scFv fragment, single domain antibody, disulfide-linked scFv fragment, etc.).
In some embodiments, the composition may include one or more agents configured to stimulate METTL3 activity in at least one body part. In some embodiments, the one or more agents may include a METTL3 agonist. As used herein, the term "METTL 3 agonist" refers to a substance that can increase the activity of the METTL3 peptide. The activity of METTL3 may refer to the ability of a unit number of METRT3 peptides in at least one body site to catalyze the methylation of RNA. In some embodiments, the METTL3 agonist may comprise a peptide, a lipid, a polysaccharide, a nucleic acid, a steroid, or any combination thereof. For example, a METTL3 agonist may include a miRNA that promotes METTL3 binding to mRNA for methylation. Such miRNAs may include, but are not limited to, miR-423-3p, miR-1226-3p, miR-330-5p, miR-668-3p, miR-1224-5p, miR-1981 and the like, or any combination thereof.
In some embodiments, the agent may be configured to increase METTL3 activity by stimulating a positive factor that enhances METTL3 activity. In some embodiments, the agent may be configured to increase the activity of one or more mirnas that promote binding of the METTL3 peptide to mRNA. In some embodiments, the agent may be configured to increase the expression of one or more mirnas that promote binding of the METTL3 peptide to mRNA. For example, the agent may comprise an enzyme that promotes the production of one or more mirnas, such as a Dicer protein and/or a fragment of a Dicer protein. As another example, an agent can include a nucleic acid and/or fragment of a nucleic acid encoding a Dicer protein or fragment of a Dicer protein. As yet another example, an agent can comprise a vector or engineered virus comprising a nucleic acid and/or fragment of a nucleic acid encoding a Dicer protein and/or fragment of a Dicer protein.
In some embodiments, the agent may be configured to increase METTL3 activity by inhibiting a negative factor that decreases METTL3 activity. By way of example only, a negative factor may include one or more small ubiquitin-like modifying (SUMO) proteins. SUMO proteins may be covalently linked to the METTL3 peptide to inhibit the catalytic ability of the METTL3 peptide. For example, SUMO proteins may include SUMO-1, SUMO-2, SUMO-3, SUMO-4, and the like, or any combination thereof. In some embodiments, the agent may inhibit the activity of one or more SUMO proteins. For example, the agent may be an antibody that binds to one or more SUMO proteins. In some embodiments, the agent may inhibit the expression of SUMO protein.
In some embodiments, the agent can increase the amount of METTL3 peptide and/or the activity of METTL3 peptide by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 150%, 200%, 300% or more.
In some embodiments, a composition for improving brain function and/or enhancing learning and/or memory may be administered orally to a subject. In some embodiments, the composition for oral administration may be formulated as a medicament, dietary supplement, food additive, beverage additive, or the like, or any combination thereof. In some embodiments, the composition may be formulated as a tablet, granule, powder, micelle, liquid, suspension, emulsion, or the like, or any combination thereof. In some embodiments, the composition may comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may need to be non-toxic and may not negatively impact the activity of the agent that increases the efficacy of METTL3 in the composition. For example, a pharmaceutically acceptable carrier may include excipients, diluents, auxiliary ingredients, and the like, or any combination thereof. Exemplary excipients can include, but are not limited to, emulsifiers, flow agents, flavoring agents, coloring agents, and the like, or any combination thereof. In some embodiments, the pharmaceutically acceptable carrier can protect the agent from oxidation and/or degradation by enzymes and low/high pH values, thereby maintaining the efficacy of the composition. For example, the pharmaceutically acceptable carrier may include a coating layer, a capsule, a microcapsule, a nanocapsule, etc., or any combination thereof. In some embodiments, the pharmaceutically acceptable carrier may have the ability to control the release of an agent that may increase the efficacy of METTL 3. Controlled release may include, but is not limited to, slow release, sustained release, targeted release, and the like, or any combination thereof. By way of example only, pharmaceutically acceptable carriers may include hydrogel capsules, microcapsules, or nanocapsules made of collagen, gelatin, chitosan, alginate, polyvinyl alcohol, polylactic acid, and the like, or any combination thereof.
In some embodiments, the composition for improving brain function and/or enhancing learning and/or memory may be a parenteral formulation. For example, the composition may be in the form of a solution, suspension, emulsion, powder, or the like for injection. In some embodiments, the composition in powder form may be dissolved or dispersed in a solution, suspension, or emulsion prior to injection. In some embodiments, the injectable formulation may further comprise other pharmaceutically injectable ingredients, such as glucose, sodium chloride, potassium chloride, and the like, or any combination thereof. In some embodiments, the composition can be administered to the subject by intravenous injection or intraperitoneal injection. In some embodiments, the composition can be stereotactically injected into at least one body part or an area proximate to the at least one body part to increase METTL3 efficacy in the at least one body part. For example, the composition can be administered to the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof.
In some embodiments, the composition may be formulated (or configured) as a suppository. As used herein, "suppository" refers to a dosage form that is inserted into the rectum, vagina, urethra, etc., or any combination thereof. In some embodiments, the suppository may include a pharmaceutically acceptable carrier that contains the active ingredients of the composition (e.g., one or more agents that increase the efficacy of METTL 3). In some embodiments, the pharmaceutically acceptable carrier may gradually dissolve, melt, or degrade (e.g., in the rectum, vagina, urethra) to release the active ingredient to produce a local or systemic effect. In some embodiments, the composition can be administered vaginally, rectally, nasally (e.g., in the form of nasal drops), otically (e.g., in the form of ear drops), intramedullary, intraarticular, intrapleurally, etc., or any combination thereof. In some embodiments, the composition may be administered to the skin of a subject. For example, the composition may be formulated as a powder, granules, nanoparticles, cream, lotion, ointment, suspension, solution, and the like. By way of example only, the composition may be applied or sprayed onto the skin of the subject (e.g., skin of at least one body part, skin of a nearby area of at least one body part).
According to another aspect of the present application, a method for improving brain function and/or enhancing learning and/or memory of a subject is provided. In some embodiments, the method may comprise administering an effective amount of a composition comprising one or more agents that increase the efficacy of METTL3 (e.g., as previously described herein) in at least one body part of the subject.
In some embodiments, the subject may be a human or an animal. In some embodiments, the subject may have a learning or memory disorder. In some embodiments, the subject may have a learning or memory deficit. In some embodiments, the subject may be afflicted with agnosia, alzheimer's disease, amnesia, traumatic brain injury, dementia, huntington's disease, parkinson's disease, west-korsakoff syndrome, or the like, or any combination thereof. In some embodiments, the subject may be mentally healthy. In some embodiments, the at least one body part of the subject may include the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof.
In some embodiments, the composition may include one or more agents configured to increase the efficacy of METTL3 in at least one body part. In some embodiments, the agent may include a METTL3 peptide. In some embodiments, reagents can include a fragment of the Mettl3cDNA sequence and/or the Mettl3cDNA sequence. In some embodiments, reagents can include engineered vectors that include a Mettl3cDNA sequence and/or a fragment of Mettl3cDNA sequence. In some embodiments, the agent can include an engineered vector comprising a METTL3mRNA sequence and/or a fragment of a METTL3mRNA sequence. In some embodiments, reagents can include engineered viruses that include a Mettl3cDNA sequence and/or a fragment of Mettl3cDNA sequence. In some embodiments, the agent can include an engineered virus that includes a METTL3mRNA sequence and/or a fragment of a METTL3mRNA sequence. More description of compositions including agents that increase the efficacy of METTL3 can be found elsewhere in the application.
In some embodiments, a composition for improving brain function and/or enhancing learning and/or enhancing memory may be administered orally to a subject. In some embodiments, the composition for improving brain function and/or enhancing learning and/or enhancing memory may be administered to the subject by parenteral administration, e.g., intravenous injection, intraperitoneal injection. In some embodiments, the composition can be stereotactically injected into at least one body part or an area proximate to the at least one body part to increase METTL3 efficacy in the at least one body part. For example, the composition can be administered to the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof. In some embodiments, the composition can be administered to a subject via vaginal, rectal, nasal, otic, intramedullary, intra-articular, intra-pleural, and the like, or any combination thereof. In some embodiments, the composition may be administered to the skin of a subject. For example, the composition may be formulated as a powder, granules, nanoparticles, cream, lotion, ointment, suspension, solution, and the like. By way of example only, the composition may be applied or sprayed onto the skin.
In some embodiments, the composition may be administered to the subject once a day, twice a day, three times a day, four times a day, etc. In some embodiments, the composition can be administered to the subject every two days, every three days, weekly, biweekly, monthly, etc.
In some embodiments, the composition may be used in combination with other drugs and/or dietary supplements to improve brain function and/or enhance learning and/or enhance memory. Exemplary drugs for improving brain function and/or enhancing learning and/or enhancing memory may include, but are not limited to, donepezil, rivastigmine, galantamine, maytansine, and the like, or any combination thereof. Exemplary core ingredients of the dietary supplement may include acetyl-l-carnitine (acetyl-l-carnitine), Bacopa monnieri (Bacopa monnieri), citicoline (citicoline), curcumin (curcumin), ginseng, huperzine A (huperzine A), and the like, or any combination thereof.
According to yet another aspect of the present application, a method for assessing learning and/or memory ability of a subject is provided. The method can comprise the following steps: (a) assessing N in at least one body part of a subject6-methyladenosine (m)6A) And/or one or more of m6The level of a-related protein; (b) m is to be6Level of A and/or m6Comparing the level of the a-related protein to a standard level; (c) determining (or evaluating) the learning ability and/or memory ability of the subject based on the comparison of (b).
In some embodiments, the at least one body part may comprise an organ, tissue, blood vessel, etc. or a portion thereof or any combination thereof. In some embodiments, the at least one body part may comprise the entire body of the subject. In some embodiments, the at least one body part may comprise one or more regions of the subject. Exemplary regions may include the head, brain, hippocampus, cortex, prefrontal cortex, neocortex, amygdala, striatum, cerebellum, and the like, or any combination thereof.
In some embodiments, to evaluate m6Level of A and/or m6Levels of a-related protein, one or more biological samples may be obtained from the subject. In some embodiments, the biological sample may include, but is not limited to, a tissue sample, a cell sample, a bodily fluid sample, and the like, or any combination thereof. Exemplary bodily fluid samples may include blood samples, mucus samples, semen samples, saliva samples, urine samples, breast milk samples, interstitial fluid, cerebrospinal fluid, lymph fluid, and the like, or any combination thereof. In some embodiments, the biological sample may be obtained from at least one body part (e.g., the hippocampus). In some embodiments, a biological sample may be obtained from one or more other body parts of a subject to assess m in at least one body part6Level of A and/or m6Levels of a-related protein. For example, the biological sample may comprise a venous blood sample obtained from a vein of the subject. In some embodiments, the biological sample may be obtained from at least one body part at any point in time. In some embodiments, the biological sample may be obtained from at least one body part after the learning test and/or the memory test. In some embodiments, the biological sample may be obtained from at least one body part after the subject has received a certain amount of training (i.e., the subject has learning and/or memory activity).
In some embodiments, a biological sample can be pretreated to obtain a pretreated biological sample. In some embodiments, a biological sample (e.g., a tissue sample) may be mashed in the pre-treatment. In some embodiments, in the pretreatment, the biological sample may contain cells and may be subjected to a cell membrane disruption processTo release intracellular RNA or protein. Exemplary operations for disrupting cell membranes may include homogenization treatment, sonication treatment, organic solvent treatment, acid treatment, base treatment, and the like, or any combination thereof. In some embodiments, total protein can be extracted from a biological sample to obtain a pretreated biological sample. In some embodiments, total RNA can be extracted from the biological sample. In some embodiments, a portion of total RNA that satisfies a predetermined condition can be isolated to obtain a measurement for m6A level of pretreated biological sample. In some embodiments, the predetermined condition may relate to the integrity of the RNA. For example, the integrity of RNA can be tested by agarose gel electrophoresis. In some embodiments, the separation may be of about 2: 1 ratio of 28S and 18S ribosomal RNA gel bands to obtain a pretreated biological sample. In some embodiments, the pretreated biological sample can be used to measure m quantitatively or qualitatively6The level of A.
In some embodiments, m6The level of A may refer to m for RNA (e.g., mRNA) in at least one body part6Degree of modification of a. In some embodiments, m of all RNAs in a biological sample may be pretreated6Intensity of A methylation site (i.e., m)6Intensity of A peak) to evaluate m6The level of A. In some embodiments, m of an mRNA that can be transcribed from a set of target genes6Evaluation of m by the intensity of A methylation sites6The level of A. In some embodiments, the set of target genes may be selected from a set of genes associated with memory and/or learning. For example, the set of target genes may include an Immediate Early Gene (IEG). In some embodiments, IEGs may include, but are not limited to, Arc, Btg2, Egr1, c-Fos, Npas4, Nr4a1, and the like, or any combination thereof. In some embodiments, the IEG may be activated quickly after learning. In some embodiments, IEGs may be essential for long-term memory development.
Evaluation of m6Exemplary methods for level a may include liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), colorimetry, methylated single nucleotide-resolved cross-linking and immunoprecipitation sequencing (miCLIP-seq) methods, methylated RNA co-immunoprecipitation-real-time quantitative PCR (MeRIP-qPCR) method, or the like, or any combination thereof. In some embodiments, for evaluating m6The method of level A may comprise contacting the pretreated biological sample with a specifically bindable moiety m6Contacting the reagent A. In some embodiments, the agent may be labeled with a detectable label. For example, the reagent may comprise a specific binding m6An antibody or fragment thereof of A. As another example, the label may include a fluorescent label, an isotopic label, or the like, or any combination thereof. m is6The level of a can be assessed on the basis of a detectable marker.
In some embodiments, m6The A-related protein may include m6A methyltransferase, m6A demethylase, and the like, or any combination thereof. E.g. m6The A methyltransferase may include, but is not limited to, METTL3, METTL14, WTAP, KIAA1429, and the like, or a fragment thereof, or any combination thereof. As another example, m6A demethylases may include, but are not limited to, FTO, ALKBH5, and the like, or fragments thereof, or any combination thereof. In certain embodiments, m6The a-related protein is METTL 3.
In some embodiments, for evaluating m6The method of the level of the A-related protein may comprise assessing m6Expression level of A-related protein and/or evaluation of m6Activity level of a related protein. In some embodiments, m can be measured in a unit volume or unit mass of the biological sample (or pretreated biological sample)6mRNA level and/or m of A-related protein6Amount of A-related protein to evaluate m6Expression level of a related protein. Evaluation of m6Exemplary methods of mRNA levels of a-related proteins can include, but are not limited to, Polymerase Chain Reaction (PCR), reverse transcription PCR (RT-PCR), in situ hybridization, knose hybridization, sequence analysis, microarray analysis, reporter gene detection, and the like, or any combination thereof. For evaluating m in a biological sample per unit volume or unit mass6Exemplary methods of measuring the amount of A-related protein may include, but are not limited to, gel electrophoresis, mass spectrometry, Quantitative Dot Blot (QDB) analysis, spectrophotometry (e.g., bicinchoninic acid assay (BCA assay), etc.,or any combination thereof. Evaluation of m6Exemplary methods of activity level of a-related protein may include, but are not limited to, enzyme-linked immunosorbent assay (ELISA), western blot, dot blot, and the like, or any combination thereof.
In some embodiments, m in at least one body part of each reference subject in the control group can be assessed6A and/or m6The level of the A-related protein is used to obtain a standard level, for example, by using the methods described above. In some embodiments, the reference subject in the control group can be mental healthy. In some embodiments, the reference subject in the control group can have normal learning and/or memory abilities. In some embodiments, the standard level may be based on m in at least one body part of a reference subject in a control group6A and/or m6A standard threshold or standard level range determined by statistical analysis of a-related protein levels.
In some embodiments, to assess the learning and/or memory abilities of a subject, the same assessment method as the control group may be used to assess m of at least one body part of the subject6A and/or m6Levels of a-related protein. In some embodiments, m of the subject may be6A and/or m6Evaluation of level of A-related protein and m6Standard level of A and/or m6Standard levels of a-related protein were compared. For example, if the assessment is above or equal to a standard threshold, or falls within a standard level range, it may be determined that the learning and/or memory ability of the subject is normal. If the assessment is below the corresponding standard threshold, or is not within a standard level range, it may be determined that the subject may have a disorder or deficit in learning and/or memory. In some embodiments, the learning and/or memory of a subject can be assessed based on a comprehensive analysis. For example, other factors to be considered in the integrated analysis may include the presence or absence of symptoms of learning and/or memory impairment or insufficiency, neuropsychological test results, Magnetoencephalogram (MEG) test results, brain imaging assessment (e.g., computed tomography: (a)CT), Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET)) results, or the like, or any combination thereof.
The present application is further described in terms of the following examples, which should not be construed as limiting the scope of the application.
Examples of the invention
Materials and methods
Animal(s) production
All mice used in the examples were born and housed in temperature-controlled (22 + -1 deg.C) rooms in ventilated cages within specific pathogen-free barriers, with a 12h light/dark illumination cycle (7:30 to 19:30 illumination times) and a humidity of approximately 50%. After birth, young mice were housed together with their mother mice, weaned on day 21 after birth, and then divided into groups by sex, and 4 to 5 mice were housed in each cage, and food and water were taken ad libitum. All wild type mice used in this procedure had a C56BL/6J genetic background and were purchased from vita River Laboratory (Beijing). To generate Mettl3 conditional knockout mice, Mettl3 was first introducedflox/floxMice were mated with CaMKII α -Cre mice (Jax #005359) to produce heterozygous mice (Mettl 3)flox/+(ii) a CamKII α -Cre), and then, the hybrid mouse is mixed with other hybrid mice or Mettl3flox/floxMice were mated to produce cKO mice (Mettl 3)flox/flox(ii) a CamKII α -Cre) and litter control mice (Mettl 3)Flox/flox). The genotype of each mouse was determined by genomic DNA extracted from the tail tip tissue. All experiments followed the guidelines of the institutional animal care and use committee of genetics and developmental biology of the chinese academy of sciences.
General conditions for behavioral testing
All behavioral tests were performed on male mice 8 to 12 weeks old. Each test was performed at a fixed time (between 8:30m and 18:30 pm) per training day. Animals were treated for 2min 3 days before behavioral testing and transferred to the testing room 24h before behavioral testing, allowing animals participating in multiple tests to rest for at least 3 days between tests. Unless otherwise stated, after testing each mouse, the device should be cleaned with 75% ethanol to prevent any deviation from olfactory cues. All behavioral tests were performed in the presence of two non-genotyped researchers.
Elevated plus maze test
The elevated plus labyrinth consists of two opposing open arms (10X 35cm) and two opposing closed arms (10X 35X 15 cm). The arms were attached to a central square (10 x 10cm) and mounted on an overhead (60 cm from the ground). The maze is made of opaque blue plastic. Each mouse was gently placed in the central area of the maze facing one open arm and then recorded with a hanging camera for 10 min. The time spent on different arms by each mouse was analyzed using EthoVision XT13 (Noduls).
Open field testing
The open field box (40X 35cm) was made of white opaque plastic. Each mouse was gently placed in the central area of the box, left to explore freely for 10min, and recorded with a hanging camera. The total travel distance and time spent by each mouse in the central region of the box was calculated using EthoVisionXT13 (Noduls).
Rotation test
The mice (4 per group) were gently placed on a spinning bar (UGO Basile) at an initial speed of 4rpm for 30s and then accelerated from 4rpm to 50rpm over 5 min. The latency of each mouse falling off the rod was recorded by a relay under the rod. Each mouse was tested 3 times with 3h intervals between each test.
New object identification testing
The new object identification test was performed using the same equipment as the open field test. On the first day, mice were placed in an open field box for 10 min. On the following day, each mouse was gently placed in the center of the box, two objects (a T-25 flask with red ink and a 50ml centrifuge tube with water) were placed in the central area, allowed to explore freely for 10min, and then the mice were returned to their home cages. After 30min, the mice were again placed back in the box (one object was replaced with a 10cm tall vase) for 5min for memory retention testing. (ii) a The behaviour of each mouse was recorded using the EhtoVisionXT 13. Frequency of investigation (f) for each subject was scored manually by two experienced researchers. The discrimination index is calculated as (f)novel-ffamliar)/(fnovel+ffamiliar)×100%。
Moris water maze test
The Morris water maze test was performed in a room in a fixed environment in a round water basin (120 cm diameter, 30cm depth, opaque by the addition of titanium dioxide, held at 21. + -. 1 ℃ C.) filled with water. A circular platform (diameter 9cm) was submerged below the water level in the center of the target quadrant. For each test, mice were gently placed in the water from one of the four quadrants, facing the pool wall, and allowed to swim for a maximum of 60s to position the hidden platform. The release quadrant is randomly altered for each test. Mice that did not find a platform were guided to the platform with long metal rods and left on the platform for 5s (test correlation between METTL3 protein abundance and learning) or 30s (all other experiments). Mice were trained twice daily, 6h apart (starting at 8:00am and 14:00pm, respectively). During the exploratory test, the platform was removed and the mice were left to swim for 60 s. The first heuristic test was performed on day 4, prior to training on day 4 (16 h after the last training on day 3), and the second heuristic test was performed on day 6, 24h after the last training on day 5. The swim path and time for each quadrant were recorded and analyzed using EthoVisionXT13 (Noduls).
Contextual fear conditioned reflex test
Mice were gently placed into conditioning chambers (Panlab, Harvard Apparatus), respectively, and left to explore for 2min, followed by one light shock (0.8mA for 2s) or 3 light shocks (0.8mA for 2s with 60s intervals). The mice were allowed to stand in the conditioning cabinet for a further 60s and then returned to the rearing cage. After 30min (short-term test) or 24h (long-term test), the mice were returned to the conditioning box for 5 min. The freezing behaviour was recorded and analysed with PACKWIN2.0.5 software (Panlab, Harvard Apparatus).
Immunohistochemistry
Fresh or perfused brain samples were instilled in 4% Paraformaldehyde (PFA) at 4 ℃ in 1xPBS for 48h fixation, then washed twice with 1xPBS, cryo-protected with 30% sucrose, frozen in tissue cryo-medium (TFM, general data) and sectioned (25-35 μm thick) with a cryostat (Leica). Sections were infiltrated and blocked for 30min at room temperature by blocking buffer, formulated in 1xPBS, containing 0.2% Triton X-100 and 2% bovine serum. The sections were then incubated overnight at 4 ℃ with primary antibody diluted with blocking buffer and secondary antibody diluted with blocking buffer for 2h at room temperature. The nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI) with a blocking agent. Antibodies used for immunofluorescence labeling were as follows:
anti-METTL 3 (1: 200, Abcam, ab195352), anti-CUX 1 (10. mu.g/ml, Abcam, ab54583), goat anti-rabbit Alexa Fluor 594 (1: 500, Abcam, ab150080) and goat anti-mouse Alexa Fluor 488 (1: 500, Abcam, ab 150113). Images were acquired using a Leica SP8 confocal microscope.
Hematoxylin-eosin (HE) staining
Brain Tissue (fixed in 4% PFA at 4 ℃ for at least 48h) was automatically dehydrated by Tissue-TekVIP5Jr (Sakura) and embedded in paraffin (56-58 ℃) by Tissue-TekTEC5 Tissue embedding machine (Sakura). Brain paraffin blocks were cut into sections 8 μm thick with a manual rotary microtome (Leica, RM2235) and these sections were mounted on poly-D-lysine coated microscope slides (CITOGLAS, 10127105P). For hematoxylin-eosin staining, sections were first dewaxed in xylene (2 times 10min each), rehydrated in alcohol (100% alcohol 5min, 95% alcohol 3min, 70% alcohol 3min, then rinsed with distilled water) and then automatically stained by Tissue-Tek Tissue section staining machine (Sukara, DRS 2000). Stained sections were dehydrated in 100% alcohol (3 times 5min each), washed in xylene (3 times 5min each), and placed in neutral balsam (Solarbio, G8590). The slide was scanned using a Nanozomer RS scanner (Hamamatsu) to obtain a full slide image.
Nie's dyeing
Nisshin staining was performed using the staining kit (Coolabler, DL0135) according to the manufacturer's instructions. Briefly, paraffin-embedded sections were deparaffinized and hydrated following the same protocol as in HE staining. The sections were then stained in cresyl violet staining solution at 56 ℃ (in 56 ℃ incubator) for 1h, washed with distilled water, and then dipped into the differentiation solution provided in the kit until the background became clear. Stained sections were dehydrated in 100% alcohol (3 times 5min each), washed in xylene (2 times 5min each), and fixed in neutral balsam (Solarbio, G8590). Slide images were obtained by scanning the slides using a Nanozomer RS scanner (Hamamatsu).
TUNEL staining
TUNEL staining was performed using the in situ cell death detection kit (Roche, 11684809910) according to the manufacturer's instructions. Briefly, cryopreserved tissue sections (prepared according to the procedures described in immunohistochemical experiments) were fixed in 4% PFA in 1XPBS for 20min at room temperature, then washed with 1XPBS for 30min and permeabilized with 0.1% sodium citrate with 0.1% Triton X-100 for 2min at 4 ℃. Each tissue section was stained with 50. mu.l of the labeling solution plus 50. mu.l of the enzyme solution in a humidified 37 ℃ incubator for 1h, rinsed 3 times in 1xPBS, and then counterstained with DAPI following the procedure described in the immunochemical experiment. Slides were imaged using a Leica fluorescence microscope (DMI 3000B). Positive and negative control staining samples were performed according to the manufacturer's instructions to confirm the validity of the staining results (data not shown).
Electrophysiological recording
Mice were deeply anesthetized (8 weeks) with sodium pentobarbital (2%, 0.3ml/100g) and decapitated. The brains were quickly removed and stored in ice-cold artificial cerebrospinal fluid (ACSF, in mM: 124NaCl, 2.5KCl, 1.2 NaH)2PO4、24NaHCO312.5D-glucose, 2CaCl2And 1.5MgSO4With 95% O2And 5% CO2Saturation, pH adjustment to 7.3, osmotic pressure adjustment to sucrose). Acute brain slices (300 μm thick) of hippocampus were prepared with a vibrating microtome (Leica) perfused with ice-cold ACSF and incubated with oxygen-containing ACSF for 1h at room temperature. The individual brain slices were then transferred to recording chambers filled with oxygen-containing ACSF (2ml/min perfusion rate) at 31. + -. 1 ℃. Visual localization of CA1 pyramidal neurons was performed using an Olympus microscope (Olympus BX 50-WI). From 110mm boronA pipette having a resistance of 4-6 M.OMEGA.was withdrawn from a silica glass capillary (Sutter Instrument). The internal solutions used were (in mM): 140K-gluconate, 2MgCl2、8KCl、10HEPES、0.2Na-GTP、2Na2-ATP (pH 7.3). Recording and analysis was performed by Axomatch 700B Amplifier (AXON), Digidata 1440A (Molecular Devices), and pCLAMP 10.6 software (Molecular Devices). Cells were monitored for series resistance and input resistance in each experiment while meeting the following requirements (high seal resistance)>1G Ω, series resistance below 25M Ω, series resistance and input resistance varied by less than 15%) for further analysis.
Minimal excitatory postsynaptic current (MEPSC) was recorded at-70 mV by keeping the cells in whole-cell voltage clamp mode. To isolate AMPA receptor-mediated mEPSC, recordings were made in ACSF containing 1. mu.M TTX and 100. mu.M PTX. Record each cell for at least 5 min. The action potential was recorded in whole-cell current-clamp mode, and was caused by a series of depolarizing current pulses between 60 and 500pA in step increments of 20 pA. A single 500pA current (500ms) was injected to measure the inter-peak interval and 3 repeated-20 pA currents (800ms) were injected to measure the fast/slow post-hyperpolarization potential (f/sAHPs).
Short-term plasticity and long-term potentiation measurements
Acute brain sections (380 μm) were prepared as described above and incubated for 1.5h at room temperature in oxygenated ACSF. Individual sections were transferred to a recording chamber (perfusion rate of 6 ml/min) at 31. + -. 1 ℃ into oxygen-containing ACSF. The extracellular recording electrode is filled with ACSF and is located in the radiation layer of the dorsal hippocampus CA1 region. A concentric stimulating electrode was placed on the radiation of CA 3. Each recording began with the measurement of the input/output ratio by adjusting the stimulation intensity from 0 to 80 μ a in 5 μ a increments. The Paired Pulse Ratio (PPR) was evaluated by applying a series of paired pulses with time intervals of 20ms, 50ms, 100ms and 200 ms. Wait 0.5-1h and further record the Long Term Potentiation (LTP) of the same brain slice. The stimulation intensity was set by stimulating 40% of the maximal response as baseline level. Stable baseline was reached at least 30min before Theta Burst Stimulation (TBS). LTP 1h was then recorded.
Virus preparation
The cDNA of Mettl3 gene was amplified from mice and cloned into T vector (TransGen, CB 101). The DPPW motif (residue 395-399) of Mettl3 (wild-type Mettl3), which is important for the binding of ademetionine, was mutated to APPA (mutant Mettl3) by PCR site-directed mutagenesis. Wild-type Mettl3 and mutant Mettl3 were subcloned into pAAV2/DJ-CMVMSC-RFP vector (HANBIO). pAAV-RC and pHelper were co-transfected into AAV-293 cells by using LipoFiter transfection reagent (HANBIO) with pAAV2/DJCMV-wildtype-Mettl3-RFP (AAV2/DJ-WT-Mettl3), pAAV2/DJ-CMV-mutated-Mettl3-RFP (AAV2/DJ-Mut-Mettl3) or pAAV2/DJ-CMV-MSC-RFP (AAV2/DJ-RFP) to produce adeno-associated virus (AAV). AAV2/DJ propagated in AAV-293 cells was purified and virus titer was measured by plaque assay. The stock solutions of AAV2/DJ-WT-Mettl3, AAV2/DJ-Mut-Mettl3 and AAV2/DJ-RFP were 1.0-1.2X 10, respectively12Plaque Forming Units (PFU)/ml. The primers used in the examples are listed in table 1.
TABLE 1 primers for vector construction and qRT-PCR
Three-dimensional positioning injection
Adult mice were anesthetized with isoflurane (8 weeks) and placed in a stereotaxic apparatus (RWD). The virus was delivered by hamilton syringe at 0.1ul per minute and the needle was allowed to stand for an additional 1min before withdrawal. Mu.l AAV2/DJ virus carrying wild-type Mettl3, mutated Mettl3 or RFP, respectively (all 1.0-1.2X 10)12PFU/ml) was injected bilaterally into the dorsal aspect of the hippocampus (relative to the chimney: AP ═ 1.9mm, ML ═ 1.2mm, DV ═ 1.3 mm). After surgery, the mice were placed on a warm pad for a short recovery time and then returned to the cage and monitored for 24 h. Mice were placed 2 weeks post-operatively and then behavioral testing was performed.
RNA isolation
Total RNA was extracted from cells or hippocampal tissue using TRNzol Universal (TIANGEN, DP 424). RNA concentration was measured using a NanoPhotometer P330(Implen), onlyOD 260/280nm ratio ofThe samples of (2) were used in subsequent experiments. RNA integrity was tested by agarose gel electrophoresis of total RNA with only 28S and 18S ribosomal RNA gel bands at a ratio of about 2: 1 was used for further studies.
Methylated RNA immunoprecipitation
Using Epimark N6Methyladenosine enrichment kit (NEB, E1610S) for methylated RNA immunoprecipitation (MeRIP). Briefly, 2. mu. l m6The a antibody was linked to protein G magnetic beads (NEB, S1430). Then, will carry m 6100. mu.g total RNA of A control RNA (Gaussia luciferase, GLuc) and unmodified control RNA (Cypridina luciferase, CLuc) were incubated with magnetic beads at 4 ℃ for 1 h. The magnetic beads were washed with reaction buffer (150mM NaCl, 10mM Tris-HCl, pH 7.5, nuclease-free H)20.1% NP-40 in O), low salt reaction buffer (50mM NaCl, 10mM Tris-HCl, pH 7.5, 0.1% NP-40 in nuclease free water) and high salt reaction buffer (500mM NaCl, 10mM Tris-HCl, pH 7.5, 0.1% NP-40 in nuclease free water) were washed twice. Purification of enriched m by phenol-chloroform extraction6A RNA。
qRT-PCR
The extracted RNA was treated with DNaseI (ThermoFisher Scientific, EN0525) and reverse transcribed to cDNA by reverse transcriptase (ThermoFisher Scientific, EP 0441). The qRT-PCR experiment was performed using SYBR Green PCR Master Mix (Toyobo, QPK-201). By using 2-ΔΔCtThe relative expression was calculated. The primers are listed in Table 1.
m6Dot blot analysis
M as described above was performed on a Bio-Dot apparatus (Bio-Rad)6Dot blot analysis, with minor modifications. Briefly, total RNA isolated from rapidly frozen (by liquid nitrogen) hippocampal tissue (male 8 weeks) was quantified using NanoPhotometer P330(Implen) and spotted onto positively charged nylon-based membranes (GE Healthcare, RPN 303B). Then 5% skim milk (Amres) dissolved in blocking buffer (LI-COR, 927-50000) was used at room temperatureco, M203) blocking the RNA sample for 2h, and mixing with anti-M6A primary antibody (1: 3000, Abcam, ab151230) was incubated overnight at 4 ℃. The RNA samples were then washed with 1 XTSST (3X 5min, CWBIO, CW00435), incubated with IRDye 800CW secondary antibody (1: 5000, Odyssey, 926-doped 32211) at room temperature for 2h, and then washed again with 1 XTSST (2X 5 min). Images were obtained from ODYSSEY CLx (LI-COR) and analyzed by ImageJ (v1.51K).
miCLIP-SMARTer-m6A-seq
Small scale single base resolution m6The A methylation group detection was performed according to the previously reported modification procedure. Briefly, 100ng of mRNA was isolated from the hippocampus of 5 mice (male 8 weeks) using the Dynabeads mRNA purification kit (Life Technologies, 61006) and fragmented using a fragmentation reagent (Life Technologies, AM8740)This was then mixed with 5. mu.g of anti-m6Antibody A was incubated in 450. mu.l immunoprecipitation buffer (50mM Tris, 100mM NaCl, 0.05% NP-40, adjusted to pH7.4) for 2h at 4 ℃ with slow rotation. The mixture was then transferred to clear flat-bottomed 96-well plates (Corning) on ice and subjected to 254nm, 0.15J/cm in a CL-1000 ultraviolet crosslinking apparatus (UVP)-2Irradiation was performed 3 times. After irradiation, the mixture was collected and incubated with 50. mu.l of prewashed protein A magnetic beads (Life Technologies, 1001D) for 2h at 4 ℃. After extensive washing (2 times) with high salt buffer (2 times, 50mM Tris, 1M NaCl, 1mM EDTA, 1% NP-40, 0.1% SDS, adjusted to pH7.4) and immunoprecipitation buffer, the microbeads were dephosphorylated with T4PNK (NEB, M0201L) for 20min at 37 ℃. RNA was eluted from the beads by proteinase K (Sigma, P2308) treatment at 55 ℃ for 1h, followed by phenol-chloroform extraction and ethanol precipitation. The purified RNA was library-constructed using the SMARTer smRNA-Seq kit for Illumina (Clontech Laboratories, 635030) according to the manufacturer's instructions and sequenced on the Illumina HiSeq X Ten platform.
RNA sequencing
Preparation of RNA according to the instructions of TruSeq RNA sample preparation kit (Illumina, FC-122-1001)And (5) sequencing the sample. Briefly, total RNA was extracted from the hippocampal tissue of the snap-frozen miceAnd used to generate a cDNA library. All samples were sequenced on the Illumina HiSeq X Ten platform. Two replicates (replicates) were sequenced for each condition (each replicate represents one mouse).
Protein extraction and western blotting
Total proteins from mouse hippocampus or primary cortical neurons were extracted by N-PER neuronal protein extraction reagent (Thermo Fisher Scientific, 87792). Protein concentrations were calculated using the Pierce Coomassie protein detection kit (Thermo Fisher Scientific, 23200). Separation of protein fractions by 10% SDS-PAGEAnd immunoblot analysis was performed with the corresponding antibodies, anti-METTL 3 (1: 1000, Abcam, ab195352), anti-beta TUBULIN (1: 2000, Abcam, ab108342), anti-GAPDH (1: 7500, Protein tech, 60004-1-AP), anti-c-FOS (1: 1000, Abcam, ab214672), anti-EGR 1 (1: 1000, Thermo Fisher Scientific, MA5-15008), anti-NPAS 4 (1: 500, Abcam, ab109984), anti-ARC (1: 1000, Abcam, ab183183) and anti-NR 4A1 (1: 1000, Abcam, ab 109180). Protein detection was performed by LI-COR Odyssey imaging system (ODYSSEY CLx, LI-COR) using IRDye secondary antibody. Relative protein levels were analyzed by ImageJ (v1.51k).
miCLIP-m6A-seq data analysis
The miCLIP-seq data were analyzed according to a preset protocol (paired end sequencing). Briefly, the linker sequence was trimmed by Cutadapt (v1.7.1) using the parameters: q 5-O5-m 20. Forward reads (forward reads) were demultiplexed (demultiplexed) using fastq2collapse. pl (CTKToolKit, v1.0.9), reverse reads (reverse reads) were first converted to reverse complement using fastx _ reverse _ completion (FASTXToolkit, v0.0.13) and then processed in the same manner. Next, the random barcode was striped using stripbarcode. pl (CTK tool kit, v1.0.9)Processing and appending it to the read headings to facilitate downstream CIMS analysis, then pulling the forward reads and converted reverse reads of each sample into a single file and aligning them with a reference Genome (mm10, USCS Genome Browser) using BWA (v0.7.12-r1039) using the parameters: n0.06-q 35. Cross-linking induced mutation sites (CIMS) were identified using the CTK tool kit (v 1.0.9): the uniquely aligned reads were selected using part alignment.pl (- -map-qual 1- -min-len 18) and PCR copies (PCR products) were folded using tag2collapse.pl (- -EM 30- -seq-error-model alignment). Py was then used to identify the mutation sites (insertions, deletions and substitutions) and CIMSC → T transition was designated using cims.pl (-n 10). Only CIMS sites with a transition number of > 2(m > 2) and a total coverage of the transition of between 1% and 50% (0.01. ltoreq. m/k. ltoreq.0.5) were selected for further analysis. Adenosine located 5' to the CIMS site was identified as m6Position A, and is labeled by bed2annode.pl (-dbkeymm 10). Meta plotR was used to analyze meta gene distribution, and fine Motifs. pl (Homerv4.8) was used to perform motif enrichment analysis (motif enrichment analysis).
RNA-seq data analysis
Paired-end, jointless reads were first aligned to a reference Genome (mm10, UCSC Genome Browser) using Tophat2(v2.1.1) with default parameters. The uniquely mapped reads were assembled into transcripts using Cufflinks (v2.2.1) and the respective abundances (FPKM) were estimated using default parameters. Cuffdiff (2.2.1) was used to identify differentially expressed genes between samples with fold change ≥ 2 and q-value ≤ 0.05 as the threshold. Gene ontology (bioprocess) enrichment analysis was performed using the metascap online service (metascap. org/gp/index. html #/main/step 1).
Cell culture
From E18.5 Mettl3 for sex Distinguishingf/fPrimary neurons were isolated from cortical tissue of embryos. Briefly, cerebral cortical tissue was isolated using a neural tissue dissociation kit (Miltenyi, 130092628) according to the manufacturer's instructions. Make the neuron at 5 × 105cells/cm2Was seeded on matrigel (Corning, 354227) precoat (Coring) and supplemented with 2% B-27(Gibco, 175040)44) 1% GlutaMAX (Gibco, 35050061), 1% non-essential amino acid solution (Gibco, 11140050) and 1% penicillin-streptomycin-neomycin antibiotic mixture (Gibco, 15640055) in a neurobasal medium (Gibco, 21103049). At 37 ℃ and 5% CO2The cells were maintained and the medium was half-changed every two days. For Mettl3 knockout and rescue experiments, neurons cultured in vitro on day 3 (DIV3) were first infected with adenoviruses expressing Cre-GFP (HANBIO, HBAD1016) or GFP (HANBIO, HBAD1009) to achieve Mettl3 conditional knockouts, and neurons cultured in vitro on day 5 (DIV5) were infected with AAV2/DJ expressing wild-type Mettl3, mutant Mettl3 or RFP. For Mettl3 overexpression experiments, neurons cultured in vitro at day 5 were infected directly with AAV2/DJ expressing wild type Mettl3, mutant Mettl3 or RFP of DIV 5. Half of the medium was collected prior to infection and neurons were incubated overnight with the corresponding virus. The next day, cells were washed and replaced with media consisting of media collected before viral infection (50%) and fresh media (50%). At days 8 to 10 of in vitro culture, neurons were stimulated with 25mM KCl (Sigma, P5405) in an incubator for 1h, and then collected for downstream analysis.
Statistical test
The results are shown as box plots (median, 25 th and 75 th percentiles) with data points representing mean ± standard error (mean ± SEM) plotted in boxes or in bar and dot plots. Statistical analysis and mapping was performed using Prism GraphPad5 or R (v3.1.3). The data distribution between groups is assumed to be normal and homovariance, but this has not been formally examined. Unless otherwise stated, comparisons between two groups were analyzed by two-tailed Student t-test (two-tailed Student's t-test), and comparisons between three or more groups were analyzed by one-way ANOVA (one-way ANOVA) and Tukey's HSD (post hoc test). The statistical test, exact P-value, sample size (n) for each experiment are specified in the legend.
The development of Long Term Memory (LTM) is crucial for learning ability and social behavior in humans and animals, but the underlying mechanisms are largely unknown. Long Term Memory (LTM) accumulated in learning or experience of the immortal memories is crucial for behavioral adaptation and intellectual development in mammals. Transformation of short-term memory into long-term memory requires synthesis of nascent proteins for synaptic consolidation, and long-term potentiation (LTP) of neurons is considered to be one of the major contributors. Although very important, the molecular mechanisms that regulate LTM formation, especially at the post-transcriptional level, may remain largely unclear.
The following examples show that the efficacy of hippocampus-dependent memory consolidation is regulated by METTL 3. Depletion of METTL3 in the hippocampus of mice reduces memory consolidation, but if given sufficient training or recovery of m of METTL36A methyltransferase function can improve learning outcome. The abundance of METTL3 in wild type mouse hippocampus was positively correlated with learning potency, whereas overexpression of METTL3 significantly enhanced long-term memory consolidation.
Example 1 Mettl3 in the hippocampus of knockout adult mice did not alter the anatomical features of the brain
Mettl3flox/floxMice were mated with CaMKII α -Cre mice to generate forebrain excitatory neuron-specific Mettl3 conditional gene knockout mice (Mettl 3)flox/flox(ii) a CaMKII α -Cre, hereinafter cKO) as shown in fig. 1A and 5A. cKO mice were alive, fertile and developed normally to adulthood, with littermate control mice (Mettl 3)flox/floxHereinafter CTRL) equivalent body and brain weight (fig. 5B and 5C). After 8 weeks, cKO mice had normal brain architecture with respect to brain morphology and the number and distribution of neurons, astrocytes and microglia, as shown in fig. 5E-5I. After the spin test, open field test, elevated plus maze test, and morris water maze test, the CTRL and cKO mice detected no differences in motor coordination, exploratory behavior, anxiety level, and swimming ability (see fig. 6A-6F). In the new object recognition test, cKO mice showed complete short-term memory (see FIG. 1B).
Example 2 depletion of METTL3 in hippocampus leads to reduced LTM forming ability and prolonged learning time
The morris water maze test was performed to examine the formation of hippocampus-dependent long-term memory (LTM) in cKO mice. In the initial training, cKO mice spent more time than the CTRL group to find hidden platforms, they could still learn gradually. On day 5, cKO mice reached the plateau as fast as CTRL (fig. 1C). Consistently, cKO mice subjected to the first challenge test after day 3 training spent significantly less time in the target quadrant than CTRL, but showed no difference compared to cKO mice subjected to the second challenge test after day 5 training (fig. 1D-1E). Fear conditioning reflex tests were performed. The cKO mice behaved identically to the CTRL mice in the contextual freeze assessment within 30min before and after a mild shock (FIG. 1F), indicating that cKO mice had normal peripheral pain and short-term memory. However, in the contextual test 24h after the first shock, the cKO mice had a freezing time of only half that of the CTRL mice, indicating that LTM formation was insufficient (fig. 1F). In conjunction with the water maze test, three mild shock trains over time increased the duration of episodic freezing behavior of CTRL and cKO mice to similar levels (fig. 1F). Overall, these data indicate that depletion of the hippocampus METTL3 results in reduced LTM formation and extended learning time, but that the final training results are unchanged after adequate training is provided.
Example 3 Long Term Potentiation (LTP) reduction leads to LTM deficiency
To investigate the physiological causes of this phenotype, whole cell patch clamping was performed on CA1 pyramidal neurons from CTRL and cKO mice. cKO mice exhibited normal resting membrane potential, membrane resistance, discharge rate, amplitude and duration, and response to injected current in CA1 neurons (fig. 2A and 10A). The synaptic transmission ability of CA1 pyramidal neurons was tested by calculating the input-output relationship (I/O) by measuring the mini excitatory post-synaptic current (mepscs) and synaptic strength. No significant change was observed for cKO neurons (fig. 2B and 10B). The contribution of paired pulses was also normal in cKO neurons, indicating that these cells have normal short-term synaptic plasticity (fig. 2C). However, LTP on the hippocampus schafer collateral pathway showed a significant decrease in the slope of the field excitatory postsynaptic potential (fEPSP) (fig. 2D and 10C), which was sufficient to cause LTM deficiency.
Example 4 formation of LTM associated with METTL3 was dependent on m of METTL36A methyltransferase function
Rescue experiments were performed by stereotactic injection of adeno-associated virus 2/DJ (AAV2/DJ) carrying the methyltransferase domain mutation (DPPW motif mutated to APPA, M3-Mut) of the Mettl3cDNA sequence (M3) or Mettl3cDNA sequence into the dorsal side of the hippocampus of 7 week old cKO mice. CTRL and cKO mice of the same age injected with AAV2/DJ bearing red fluorescent protein were used as positive and negative controls (CTRL + RFP, cKO + RFP), respectively. After 2 weeks of recovery, the four groups of mice were examined using the morris water maze test and the conditioned fear test. As expected, cKO + M3 and cKO + Mut mice synthesized more METTL3 protein in hippocampus than in cKO + RFP group, but M was detected only in cKO + M3 mice6A abundance increased (fig. 3A). Thus, cKO + M3 mice performed as well as the CTRL + RFP group in the water maze and conditioned fear test, but cKO + Mut mice did not show any improvement compared to the cKO + RFP group (fig. 3B-3D), indicating that METTL 3-associated LTM formation is dependent on M of METTL36A methyltransferase function. Again, after 3 shocks of 5 days of water maze and conditioned fear training, all four groups of mice reached the same level of performance (fig. 3B-3D), demonstrating the ability of cKO + Mut mice to form LTMs after full training.
Example 5m6Role of A in memory consolidation
Collected for miCLIP-m 0min (initial), 30min, 1h and 4h after conditioned situational fear training by using one shock6CTRL mice of A-seq Single base m in Hippocampus tissue6A methylation detection (FIG. 4A). At the above time points, expressed genes (hereinafter referred to as m) corresponding to 4424, 3440, 3643 and 5063, respectively, were determined6A-tag gene) 8941, 5995, 6367 and 10853 m6The A site (with the RRACU motif and distributed near the stop codon) (FIG. 4B). Wherein about 15-20% of the expressed genes are represented by m6A was specifically modified and resulted in modification of the 1184 gene at all time points. The gene ontology analysis shows that the gene is continuously repairedIn decorated genes, synaptic signaling and neural development functions were abundant, in genes specifically modified within 30min and 1h, membrane-associated protein deposition was abundant, and in 4h specific genes (FIG. 4C), axon projection function was abundant by 35, consistent with the mechanism of memory consolidation. RNA-seq detected m between 0min (initial), 30min, 1h and 4h collection of CTRL and cKO mouse hippocampal tissue following contextual fear conditioning training6There were no significant differences in expression of the a-tag gene (fig. 4D, 11A and 11B), indicating that transcriptional level regulation of cells in cKO mouse hippocampus remained intact.
To investigate the seemingly contradictory phenomena between functional deficits and mRNA expression consistency between CTRL and cKO mice, western blotting was used to examine the protein abundance of 6 well-studied early response genes (IEGs), which should be activated rapidly after learning, and which are essential for LTM formation. M was detected on transcripts of all 6 genes by MeRIP-qPCR of CTRL samples (FIGS. 5A and 12)6And (C) modifying. However, although all of these genes showed similar learning-induced changes in expression in CTRL and cKO samples at RNA level (fig. 5B), they all produced less protein in cKO mice than in CTRL mice (fig. 5C-5F), suggesting that the prolongation of the learning process in cKO mice may be due to the lack of m6A is caused by insufficient protein synthesis. For further study, expression of Arc and c-Fos was induced in cultured primary cortical neurons by KCl treatment. Consistent with the in vivo data, Mettl3-KO neurons produced less ARC and C-FOS proteins than CTRL, but this difference could be rescued by introducing wild-type METTL3 into cKO neurons (FIGS. 5C-5E). Likewise, METTL3 with a mutated methyltransferase domain failed to rescue protein translation defects, suggesting m6The important role of a in such regulation.
Example 6 RNA m in hippocampus6A-induced differences are the cause of individual differences in memory forming potency
The above findings indicate that the abundance of the hippocampus METTL3 in individuals may explain the changes in its spatial learning potency. Indeed, in the Morris water maze test, genes were found in wild type mice (8 weeks, males)Moderate positive correlation between METTL3 protein abundance and learning potency (r ═ 0.378) in the hippocampus (fig. 6A). In the first probing test, mice with more METTL3 tended to spend more time on the target quadrant, but after sufficient training (probing test II), this correlation disappeared (fig. 6A). To further characterize the relationship between METTL3 abundance and learning potency, AAV2/DJ virus carrying wild-type METTL3, methyltransferase domain mutated METTL3 or RFP was injected bilaterally into the dorsal hippocampus of wild-type mice (WT + M3, WT + Mut and WT + RFP, respectively) (fig. 13A). As expected, the over-expressed Mettl3 significantly improved the learning potency of the mice in both the morris water maze test and the one-shock conditioned contextual fear test, but the over-expression of Mettl3 with a mutated methyltransferase domain had no effect (fig. 6B-6D), indicating that Mettl3 modulates m by6The formation of a plays a role. Also, with appropriate training (three shock fear conditioning training), no behavioral differences were detected between mettl3 overexpression and the other groups (fig. 6D). Mettl3 overexpressed in KCl-treated primary cortical neurons also significantly enhanced the translation of IEGsArc and c-Fos compared to wild-type controls (FIGS. 6E and 13B).
As shown above, METTL3 was demonstrated to enhance hippocampus-dependent LTM by promoting activity-induced translational potency of IEG. In this application, METTL3 was demonstrated to mediate LTM formation. In this application, Mettl3 in knockout adult mouse hippocampus does not alter brain anatomical features or short-term memory-related electrophysiological activity, a phenomenon that should be distinguished from developmental stage studies in which depletion of Mettl3 causes severe defects in the whole brain. Thus, m6The dynamic functional preference of the A-modified genes at different post-training points (FIG. 4B) also indicates that m6The A modified gene responds rapidly to the stimulus, suggesting that other stimulus-related physiological responses may also be related to m6A is related. Interestingly, despite the lack of Mettl3/m6A resulted in a reduction in learning performance, but the same training effect was achieved after prolonged water maze training or excessive shock, indicating Mettl3/m6A is useful in regulating memory consolidation but is not necessarily requiredHas little effect. Evidence of expression of IEG may further support this conclusion, since induction of IEG after training can still be detected at the mRNA and protein levels of cKO mice, but protein levels of cKO mice are much weaker than those of CTRL mice. Therefore, repeated induction of IEG proteins in reduced abundance may be able to achieve the desired synaptic consolidation effect. The correlation of METTL3 abundance with mouse learning capacity suggests that this molecule in hippocampus may be responsible, in part, for individual differences in memory-forming potency, and that drugs that enhance METTL3 expression may improve learning capacity and slow memory loss associated with age or disease.
Fig. 1A-1F show exemplary results of processes by which the acquired absence of Mettl3 in the hippocampus may prolong LTM consolidation, according to some embodiments of the present application. FIG. 1A shows the characteristics of Mettl3 conditional gene knockout in the CA1 region of 8-week male mice brains (scale bar, 100 μm). FIG. 1B shows a control group (CTRL, Mettl3)f/f) And Mettl3 conditional knockouts (cKO, Mettl3)f/f(ii) a CaMKII α -Cre) mice were tested in a new object recognition test (CTRL, n 13 mic; cKO, n is 10 mic). Figure 1C shows the results of the morris water maze test for five consecutive training days. FIG. 1D shows quadrant occupancy of CTRL and cKO mice in two probing tests ("a" for CTRL and "b" for cKO). Fig. 1E shows a corresponding representative swim path. Fig. 1F shows the freezing behavior before (initial) and 30min (short term) after one shock fear condition, and during contextual testing 24h after one or three shock exercises. In fig. 1D-1F, CTRL, n ═ 14 mice; cKO, n is 13 mice. Student's t test, P<0.05,**P<0.01,***P<0.001, N.S, no significance.
Figures 2A-2D show exemplary results of electrophysiological testing of a hippocampus knockout Mettl3 according to some embodiments of the present application. Fig. 2A shows representative traces and numbers of action potentials in CTRL and cKOCA1 pyramidal neurons (3 mice per group, n ═ 10 hippocampus slices) in response to stimuli of different intensities. Figure 2B shows a representative trace of mESPC and the distribution of cumulative probability of mepscs amplitude and frequency. The inset shows a comparison of the mean values. Fig. 2C shows the paired pulse ratio for different stimulation intervals in CTRL and cKO groups (3 mice per group, n ═ 9 hippocampus slices). Fig. 2D shows the field EPSP slope change in the CTRL and cKO groups after a single Theta Burst Stimulation (TBS). Inset shows representative traces at baseline and 1h post-TBS induction (3 mice per group, n ═ 9 hippocampal sections). Student t test, n.s., no significance.
FIGS. 3A-3D illustrate indicating METTL3 via m thereof according to some embodiments of the present application6A methyltransferase function regulates exemplary consequences of long-term memory formation. FIG. 3A shows cKO METTL3 and m in the hippocampus of mice6And (4) recovering the A. # 1 and #2 represent two biological replications. FIG. 3B shows that wild-type Mettl3(M3) was tested in the Moris water maze test instead of having a lack of M6Mettl3(Mut) for a methyltransferase function was reintroduced into hippocampus, saving cKO mice for learning delay. FIG. 3C shows probing tests of the panel of FIG. 3B ("a" for CTRL + RFP, "B" for cKO + M3, "C" for cKO + Mut, "d" for cKO + RFP). Upper plate, target and non-target quadrant occupancy frequencies; lower panel, representative swimming path of the upper panel. In fig. 3B and 3C, RFP: controlling injection; CTRL + RFP, n ═ 10 mice; cKO + M3, n ═ 10 mice; cKO + Mut, n-8 mice; cKO + RFP, n ═ 9 mice. Figure 3D shows that reintroduction of wild-type Mettl3 rescued the learning deficit of cKO mice in fear conditioning testing (CTRL + RFP, n-10 mice; cKO + M3, n-9 mice; cKO + Mut, n-10 mice; cKO + RFP, n-10 mice). FIGS. 3B-3D, ANOVA and Tukey's HSD post hoc testing, P<0.05,**P<0.01,***P<0.001, n.s., no significance.
FIGS. 4A-4D illustrate dynamically adjusting m during memory consolidation according to some embodiments of the present application6Exemplary results of A methylation. Fig. 4A shows an experimental design of a sampling strategy. FIG. 4B shows m before and after fear conditioning reflex training6A distribution (upper panel), motif (middle panel) and m6Number of genes marked A (lower panel). FIG. 4C shows common and time-point specific m6And (3) enriching and analyzing a Gene Ontology (GO) of the A-tag gene. Nodule size proportional to associated basis factor, tone scale representationThe phrase enhances meaning. FIG. 4D shows m between CTRL and cKO hippocampus at different points in time6And (4) comparing the expression of the A marker gene. r is the Pearson correlation coefficient.
FIGS. 5A-5F illustrate m according to some embodiments of the present application6A promotes translation of early response genes upon activity induction. FIG. 5A shows early response genes (IEG) by m6A labeled and were induced by comparative fear conditioning training in the hippocampus of CTRL and cKO mice (fig. 5B). FIGS. 5C-5E show that cKO mouse IEG is impaired in translation after training and can pass Mettl3f/fM of METTL3 in primary neurons6A methyltransferase activity was used for rescue. Fig. 5C shows western blots and fig. 5D-5E show relative quantitation. Fig. 5F shows immunofluorescence images of EGR1 in the CA1 region before and after fear conditioning reflex training (1h and 4 h). Student's t test, P<0.05、**P<0.01、***P<0.001, n.s., without significance, in fig. 5C-5E, n-3 repeats, and in fig. 5B, n-2 repeats.
Fig. 6A-6E show exemplary results of overexpression of METTL3 enhancing the development of long term memory according to some embodiments of the present application. Figure 6A shows the correlation between hippocampus METTL3 levels and mouse performance in two probing tests. n-20 mice. r, representing the pearson correlation coefficient. 6B-6C show the Morris water maze test. Figure 6D shows a fear conditioned reflex test, which indicates that the learning efficacy of WT + M3 mice is superior to other mice. WT + Mut and WT + RFP mice were shock trained once, but not three times. Fig. 6E shows that overexpression of Mettl3 enhances translation of IEGs in primary neurons after KCl treatment. In fig. 6B-6E, student t-test, P <0.01, P <0.001, n.s., was not significant. In fig. 6B-6D, n is 10 mice/group. In fig. 6E, n is 3 repeats.
FIG. 7 illustrates an exemplary proposed model according to some embodiments of the present application. In FIG. 7, METTL3 mediated m6A modification can modulate long-term memory consolidation by increasing the translation efficiency of early response genes in the mouse hippocampus. As shown, long training may offset m6Learning deficit due to A deficiency, whereas of METTL3Overexpression may enhance learning performance.
Figures 8A-8H show exemplary results of brain gross morphology characterization of Mettl3 cKO mice according to some embodiments of the present application. FIG. 8A shows that CaMKII α -Cre-mediated KO of Mettl3 reduces m in hippocampus6A abundance (n ═ 3 repeats). cKO mice developed normally to adulthood, normal body weight (fig. 8B), normal brain weight (fig. 8C), normal brain morphology (fig. 8D-8G) and no apoptosis was observed in the hippocampus (8 weeks) (fig. 8H). Student's t test, P<0.05,**P<0.01, n.s., no significance; in fig. 8B-8C, n-8 mice/group.
Figures 9A-9F show exemplary results of Mettl3 cKO mice showing no differences in locomotion, exploration, and anxiety compared to CTRL, according to some embodiments of the present application. Fig. 9A shows the rotation test measuring the motor coordination of the animals (CTRL, n-14 mice; cKO, n-11 mice). Fig. 9B shows the total movement distance within 10min on an open field. Fig. 9C shows the duration and representative motion trajectory of mice staying in the central area (n-10 mice/group). Figure 9D shows the duration and representative traces of mice in either the open or closed arms (CTRL, n-12 mice; cKO, n-11 mice). Fig. 9E shows a representative heat map showing that the preference of the animal for new objects (filled circles) is higher than the preference for old objects (dashed circles). Fig. 9F shows the total swimming distance of the mice (CTRL, n ═ 11 mice; cKO, n ═ 10 mice). Student t test, n.s., no significance.
Fig. 10A-10C show exemplary results of characterization of electrophysiological properties of cKO mice, according to some embodiments of the present application. Fig. 10A shows measurements from whole-cell recordings of CA1 pyramidal neurons. fhhp, fast hyperpolarized post-potential; sAHP, potential after slow post-hyperpolarization. Fig. 10B shows the input-output curves of the fEPSP in the CA1 region in response to different stimuli. Fig. 10C shows the slope of fEPSP over the last 10min of LTP recording. Baseline was measured during the last 10min before the theta burst stimulation. In fig. 10A, 10 brain slices were taken from 3mice per group. In fig. 10B-10C, 9 brain sections were taken from 3mice per group. Student t test, P <0.001, n.s., no significance.
11A-11B show exemplary results of transcriptome change analysis at early time points after training according to some embodiments of the present application. Figure 11A shows a volcano plot with no significant transcriptome abundance changes (FPKM) between CTRL and cKO mice at all time points. m is6The genes of the A-tag are each color-coded. FIG. 11B shows a heatmap of cKO and CTRL mice expression of key genes involved in synaptic function at different time points (except not from miCLIP-m)6All genes listed, except Cdk5 identified in A-seq, were found to be m6A modification). Both CTRL and cKO groups contained two RNA-seq replicates.
Figure 12 shows exemplary results of MeRIP-qPCR validation according to some embodiments of the present application. Positive and negative controls for the MeRIP-qPCR experiment (relevant to figure 5A). n-3 replicates.
Fig. 13A-13B show exemplary results of overexpression of Mettl3 in hippocampus or primary neurons according to some embodiments of the present application. FIG. 13A shows that overexpression of Mettl3 in mouse hippocampus increases m6And (4) abundance of A. Student's t test, P<0.01,***P<0.001, n.s., no significance. Figure 13B shows that overexpression of Mettl3 in primary neurons enhanced translation of IEG (induced by KCl treatment). n-3 replicates.
It should be noted that the above examples are provided for illustrative purposes only and are not intended to limit the scope of the present application. Many variations and modifications may be made to the teachings of the present application by those of ordinary skill in the art. However, such changes and modifications do not depart from the scope of the present application.
Having thus described the basic concepts, it will be apparent to those of ordinary skill in the art having read this application that the foregoing disclosure is to be construed as illustrative only and is not limiting of the application. Various modifications, improvements and adaptations of the present application may occur to those skilled in the art, although they are not explicitly described herein. Such modifications, improvements and adaptations are proposed in the present application and thus fall within the spirit and scope of the exemplary embodiments of the present application.
Also, this application uses specific language to describe embodiments of the application. For example, "one embodiment," "an embodiment," and "some embodiments" mean a particular feature, structure, or characteristic described in connection with at least one embodiment of the present application. Therefore, it is emphasized and should be appreciated that two or more references to "an embodiment" or "one embodiment" or "an alternative embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, certain features, structures, or characteristics of one or more embodiments of the application may be combined as appropriate.
Additionally, the order in which elements and sequences of the processes described herein are processed, the use of alphanumeric characters, or the use of other designations, is not intended to limit the order of the processes and methods described herein, unless explicitly claimed. While various presently contemplated embodiments of the invention have been discussed in the foregoing disclosure by way of example, it is to be understood that such detail is solely for that purpose and that the appended claims are not limited to the disclosed embodiments, but, on the contrary, are intended to cover all modifications and equivalent arrangements that are within the spirit and scope of the embodiments herein. For example, although the system components described above may be implemented by hardware devices, they may also be implemented by software-only solutions, such as installing the described system on an existing server or mobile device.
Similarly, it should be appreciated that in the foregoing description of embodiments of the application, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the application aiding in the understanding of one or more of the various embodiments. This method of application, however, is not to be interpreted as reflecting an intention that the claimed subject matter to be scanned requires more features than are expressly recited in each claim. Indeed, the embodiments may be characterized as having less than all of the features of a single embodiment disclosed above.
Claims (58)
1. A method, comprising:
administering to a subject to improve brain function or enhance learning or memory of the subjectThe composition of (a), comprising enhancing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
2. The method of claim 1, wherein the subject is a human or an animal.
3. The method of any one of claims 1-2, wherein the subject has a learning or memory disorder.
4. The method of any one of claims 1-2, wherein the subject has a learning or memory deficit.
5. The method of any one of claims 1-2, wherein the subject has agnosia, alzheimer's disease, amnesia, brain trauma, or dementia.
6. The method of any one of claims 1-2, wherein the subject is psychologically healthy.
7. The method of any one of claims 1-6, wherein the at least one body part of the subject comprises the brain of the subject.
8. The method of any one of claims 1-6, wherein the at least one body part of the subject comprises a hippocampus of the subject.
9. The method of any one of claims 1-8, wherein the one or more agents are configured to increase the amount of METTL3 in the at least one body part.
10. The method of claim 9, wherein the one or more agents comprise a METTL3 peptide.
11. The method of claim 9, wherein the one or more reagents comprise a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
12. The method of claim 9, wherein the one or more reagents comprise an engineered vector comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
13. The method of claim 9, wherein the one or more reagents comprise an engineered virus comprising a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
14. The method of claim 13, wherein the virus comprises an adeno-associated virus, an adenovirus, a lentivirus, or a sendai virus.
15. The method of claim 9, wherein the one or more agents are configured to increase METTL3 expression by stimulating a positive factor that enhances METTL3 expression.
16. The method of claim 9, wherein the one or more agents are configured to increase METTL3 expression by inhibiting a negative factor that decreases METTL3 expression.
17. The method of claim 16, wherein the one or more reagents comprise an antibody.
18. The method of any one of claims 1-8, wherein the one or more agents are configured to stimulate METTL3 activity in the at least one body part.
19. The method of claim 18, wherein the one or more agents comprise a METTL3 agonist.
20. The method of claim 18, wherein the one or more agents are configured to increase METTL3 activity by stimulating a positive factor that enhances METTL3 activity.
21. The method of claim 9, wherein the one or more agents are configured to increase METTL3 activity by inhibiting a negative factor that decreases METTL3 activity.
22. The method of any one of claims 1-21, wherein administering a composition to a subject comprises applying the composition to the skin of the subject.
23. The method of any one of claims 1-21, wherein administering a composition to a subject comprises injecting the composition into the subject.
24. The method of any one of claims 1-21, wherein administering a composition to a subject comprises orally administering the composition to the subject.
25. The method of any one of claims 1-21, wherein the composition is configured as a suppository.
26. A method, comprising:
a composition for administration to a subject to enhance learning ability of the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
27. A method, comprising:
a composition for administration to a subject to enhance memory in the subject, the composition comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
28. A method, comprising:
a composition for administration to a subject to enhance long term memory consolidation in the subject, the composition comprising an increase of METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
29. A method, comprising:
a composition for administration to a subject to enhance long term memory consolidation in said subject, said composition comprising an increase in METTL3 (N) in the hippocampus of said subject6-adenosine methyltransferase 70kDa subunit).
30. A method, comprising:
a composition for administration to a subject to improve brain function in the subject suffering from a mental disorder, the composition comprising increasing METTL3 (N) in the hippocampus of the subject6-adenosine methyltransferase 70kDa subunit).
31. A method, comprising:
a composition for administration to a subject to enhance long term memory consolidation in said subject having a memory deficit, said composition comprising an increase in METTL3 (N) in the hippocampus of said subject6-adenosine methyltransferase 70kDa subunit).
32. A method, comprising:
a composition for administration to a subject to enhance long term memory consolidation in said subject who does not suffer from a memory deficit, said composition comprising an increase in METTL3 (N) in the hippocampus of said subject6-adenosine methyltransferase 70kDa subunit).
33. A method, comprising:
a composition for administration to a subject to improve brain function or to enhance learning or memory in said subject, said composition comprising an increase in N in at least one body part of said subject6-methyladenosine (m)6A) An abundance of one or more reagents.
34. A method of assessing learning or memory ability of a subject, comprising:
(a) assessing N in at least one body part of the subject6-methyladenosine (m)6A) The level of the protein of interest;
(b) m is to be6A or said m6Comparing the level of the a-related protein to a standard level; and
(c) determining the learning or memory ability of the subject from the comparison of (b).
35. The method of claim 34, wherein m is6The A-related protein is METTL3 protein.
36. The method of claim 34, wherein the at least one body part of the subject comprises a hippocampus of the subject.
37. The method of claim 34, wherein said standard level is determined by evaluating said m for at least one body part of a control subject6Levels of a-related protein.
38. A composition configured to improve brain function or enhance learning or memory in a subject, comprising increasing METTL3 (N) in at least one body part of the subject6-adenosine methyltransferase 70kDa subunit).
39. The composition of claim 38, wherein the subject is a human or an animal.
40. The composition of any one of claims 38-39, wherein the subject has a learning or memory disorder.
41. The composition of any one of claims 38-39, wherein the subject has a learning or memory deficit.
42. The composition of any one of claims 38-39, wherein the subject has agnosia, Alzheimer's disease, amnesia, brain trauma, or dementia.
43. The composition of any one of claims 38-39, wherein the subject is mental healthy.
44. The composition of any one of claims 38-43, wherein the at least one body part of the subject comprises the brain of the subject.
45. The composition of any one of claims 38-43, wherein the at least one body part of the subject comprises the hippocampus of the subject.
46. The composition of any one of claims 38-45, wherein the one or more agents are configured to increase the amount of METTL3 in the at least one body part.
47. The composition of claim 46, wherein the one or more agents comprise a METTL3 peptide.
48. The composition of claim 46, wherein the one or more reagents comprise a Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
49. The composition of claim 46, wherein the one or more reagents comprise an engineered vector comprising the Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
50. The composition of claim 46, wherein the one or more reagents comprise an engineered virus comprising the Mettl3cDNA sequence or a fragment of the Mettl3cDNA sequence.
51. The composition of claim 50, wherein the virus comprises an adeno-associated virus, an adenovirus, a lentivirus, or a Sendai virus.
52. The composition of claim 46, wherein the one or more agents are configured to increase METTL3 expression by stimulating a positive factor that enhances METTL3 expression.
53. The composition of claim 46, wherein the one or more agents are configured to increase METTL3 expression by inhibiting a negative factor that decreases METTL3 expression.
54. The composition of claim 53, wherein the one or more agents comprise an antibody.
55. The composition of any one of claims 38-45, wherein the one or more agents are configured to stimulate METTL3 activity in the at least one body part.
56. The composition of claim 55, wherein the one or more agents comprise a METTL3 agonist.
57. The composition of claim 55, wherein the one or more agents are configured to increase METTL3 activity by stimulating a positive factor that enhances METTL3 activity.
58. The composition of claim 46, wherein the one or more agents are configured to increase METTL3 activity by inhibiting a negative factor that decreases METTL3 activity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/100721 WO2020034127A1 (en) | 2018-08-15 | 2018-08-15 | Compositions and methods for assessing or improving brain function, learning ability or memory |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112585270A true CN112585270A (en) | 2021-03-30 |
CN112585270B CN112585270B (en) | 2023-12-05 |
Family
ID=69524969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880096673.8A Active CN112585270B (en) | 2018-08-15 | 2018-08-15 | Compositions and methods for assessing or improving brain function, learning ability, or memory |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112585270B (en) |
WO (1) | WO2020034127A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113470077A (en) * | 2021-07-15 | 2021-10-01 | 郑州布恩科技有限公司 | Mouse open field experiment movement behavior analysis method based on key point detection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207557A (en) * | 2015-01-26 | 2017-09-26 | 中国科学院动物研究所 | MiRNA is to m6A modifies the regulation and control method and its application of level |
CN107636171A (en) * | 2015-03-04 | 2018-01-26 | 威拉赛特公司 | Use expression and the method for the generation of sequence variants information evaluation disease or risk of recurrence |
CN108103090A (en) * | 2017-12-12 | 2018-06-01 | 中山大学附属第医院 | RNA Cas9-m6A modified vector system for targeting RNA methylation, and construction method and application thereof |
US20190100801A1 (en) * | 2015-10-28 | 2019-04-04 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
-
2018
- 2018-08-15 CN CN201880096673.8A patent/CN112585270B/en active Active
- 2018-08-15 WO PCT/CN2018/100721 patent/WO2020034127A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207557A (en) * | 2015-01-26 | 2017-09-26 | 中国科学院动物研究所 | MiRNA is to m6A modifies the regulation and control method and its application of level |
CN107636171A (en) * | 2015-03-04 | 2018-01-26 | 威拉赛特公司 | Use expression and the method for the generation of sequence variants information evaluation disease or risk of recurrence |
US20190100801A1 (en) * | 2015-10-28 | 2019-04-04 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
CN108103090A (en) * | 2017-12-12 | 2018-06-01 | 中山大学附属第医院 | RNA Cas9-m6A modified vector system for targeting RNA methylation, and construction method and application thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113470077A (en) * | 2021-07-15 | 2021-10-01 | 郑州布恩科技有限公司 | Mouse open field experiment movement behavior analysis method based on key point detection |
Also Published As
Publication number | Publication date |
---|---|
WO2020034127A1 (en) | 2020-02-20 |
CN112585270B (en) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Villeda et al. | Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice | |
Larson et al. | Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility | |
Devaraju et al. | Haploinsufficiency of the 22q11. 2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium | |
Maier et al. | The dorsal raphe nucleus is a site of action mediating the behavioral effects of the benzodiazepine receptor inverse agonist DMCM. | |
Wang et al. | From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with Toxoplasma gondii | |
Zhou et al. | Astroglial dysfunctions drive aberrant synaptogenesis and social behavioral deficits in mice with neonatal exposure to lengthy general anesthesia | |
Speisman et al. | Environmental enrichment restores neurogenesis and rapid acquisition in aged rats | |
Taliaz et al. | Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis | |
Konopka et al. | MicroRNA loss enhances learning and memory in mice | |
Amigó et al. | The absence of 5-HT4 receptors modulates depression-and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: Adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor | |
Jha et al. | Monocarboxylate transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during aging | |
Guan et al. | The mechanism of enriched environment repairing the learning and memory impairment in offspring of prenatal stress by regulating the expression of activity-regulated cytoskeletal-associated and insulin-like growth factor-2 in hippocampus | |
Xiong et al. | Vi4-miR-185-5p-Igfbp3 network protects the brain from neonatal hypoxic ischemic injury via promoting neuron survival and suppressing the cell apoptosis | |
Wu et al. | Impairments of spatial learning and memory following intrahippocampal injection in rats of 3-mercaptopropionic acid-modified CdTe quantum dots and molecular mechanisms | |
Zhao et al. | Prenatal cocaine exposure impairs cognitive function of progeny via insulin growth factor II epigenetic regulation | |
Xu et al. | MicroRNA-325-3p prevents sevoflurane-induced learning and memory impairment by inhibiting Nupr1 and C/EBPβ/IGFBP5 signaling in rats | |
Zhang et al. | Mouse astrocytes promote microglial ramification by releasing TGF-β and forming glial fibers | |
Saraceno et al. | Consequences of excessive plasticity in the hippocampus induced by perinatal asphyxia | |
Schob et al. | Cognitive impairment and autistic-like behaviour in SAPAP4-deficient mice | |
Chai et al. | Sevoflurane inhibits neuronal migration and axon growth in the developing mouse cerebral cortex | |
Fuchs et al. | Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder | |
Chen et al. | Pten is a key intrinsic factor regulating raphe 5-HT neuronal plasticity and depressive behaviors in mice | |
Kang et al. | Downregulation of microRNA‐124‐3p promotes subventricular zone neural stem cell activation by enhancing the function of BDNF downstream pathways after traumatic brain injury in adult rats | |
Sun et al. | CHIT1-positive microglia drive motor neuron ageing in the primate spinal cord | |
Han et al. | SVCT2–mediated ascorbic acid uptake buffers stress responses via DNA hydroxymethylation reprogramming of S100 calcium-binding protein A4 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |